 
Document type:  Study Protocol  
Official Title:  Intima versus adventitia drug delivery to 
elucidate mechanisms of restenosis: 
magnetic resonance imaging  
Study ID: [REMOVED]  
Document Date:  10 October 2019  
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926162] 2019  Page 2 of 72 
  
INtima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: 
Magnetic Resonance Imaging  
INVADER MRI  
 
CLINICAL RESEARCH  PROTOCOL  
 
Investigator:  David Saloner , Ph.D.  
Professor  of Radiology and Biomedical 
Imaging  
University of [LOCATION_004], San Francisco  
Director, Vascular Imaging Research Center  
 
Locations:  San Francisco VA Medical Center  
[ADDRESS_926163]. MS#[ADDRESS_926164] 2015  New Release  
1.1 21 DEC EMBER 2015  Changed name [CONTACT_683949].  
Revised Study Rationale for grammar.  
Revised Primary and Secondary Objectives for 
consistency with grant.  
Revised language related to ‚ÄúInvestigational 
Product‚Äù, Dispensing and Storage Instruction to 
clarify DEX is not an investigational product.  
Changed wording of Secondary Aim #3 ( Ktrans) to 
specify measurement at 6 months  
Sec. 9.10 ‚ÄúResearch MRI‚Äù - removed Ktrans at 24 
hours and 12 mon ths 
Changed Sec 9.2, Research lab measurements to 
include assessment of inflammatory markers at 12 
months to match Secondary Aim #2.  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926165] 2019  Page 3 of 72 
 Updated screening exclusion criteria  to the patient 
is expected to live 1 -year or longer . Added  
exceptions to known active malignancy . 
Revised Procedural Inclusion/Exclusion Criteria to 
better define eligible lesions, concomitant 
procedures and medications.  
Changed maximum lesion length from < 20 cm to 
entire superficial femoral/popliteal artery  
Upda ted Treatment Segment Registration 
procedure to clarify when the investigator has 
discretion for choosing an index lesion.  
Updated Treatment Segment Registration to 
include origin of profunda femoris artery as key 
landmark  
Changed Sec. 9.8.2 ‚ÄúOrder of Oper ations‚Äù to clarify 
the Core Lab will grade infusion success  
Removed Sec. 9.9 Clinical MRA due to differences 
in clinical practices between sites  
Added Sec. 9.10.2 Research MRI Protocol with 
specific language about processing modalities  
Added language to ‚ÄúR esearch MRI‚Äù procedure 
description regarding blind reading of MRI studies.  
Changed window for [ADDRESS_926166]  & ABI as part of vascular exam  
Change to Appendix 1 ‚Äì clarified appropriate tube 
type for MCP -1 
Added Appendix 6: Lutonix DCB IFU  
Added Appendix 7: I NPACT  Admiral DCB IFU  
Added Appendix 8: Walking Impairment 
Questionnaire (WIQ)  
1.[ADDRESS_926167] of Abbreviations  
Revised grammar of inclusion/exclusion criteria, for 
clarity  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926168] 2019  Page 4 of 72 
 Standardized terminology throughout protocol  
Changed Sec 9.8  Order of Operations, item s no.4 
& no.[ADDRESS_926169] modification of Sec 9.9.2  
Change d Sec 9.9.2 to clarify the  method used for 
determining the MRI scan  location  
Added Sec 9.9.3 Pre -Reintervention MRI to specify 
conditions  for imaging in the event of an unplanned 
visit for index leg reintervention  
Revised Sec 10  Schedule of Assessments  for 
accuracy, including Inclusion/Exclusion criteria , 
Rutherford Category , Index Lesion Registration  & 
PTX Treatment  
Changed Sec 11.2 Visit 2: Procedure (Day 0) to 
match  Sec 9.1.4  Concomitant Medications and Sec 
10 Schedule of Assessments by [CONTACT_683904] 0 assessments  
Added Sec 11.8  Unplanned Visit for Index Leg 
Reintervention  
Change in Data Management team  
To eliminate possible confusion, all instances of the 
term ‚Äústudy drug‚Äù have been substituted with more 
accurate terminology. This trial uses FDA approved 
drugs and devices in accordance with their IFUs. 
For more information, please refer to Section 8.[ADDRESS_926170] Screening Inclusion and Exclusion  
Addition of ILLUMENATE PI[INVESTIGATOR_683872] 1.1 under Drug Coated Balloon  
Additi on of literature references for new studies in 
Section 1.2 regarding New Drug Coated Balloon   
Addition of Stellarex DCB  Risk in Section [IP_ADDRESS]   
Inlcude eGFR criteria in section 6.[ADDRESS_926171] 2017  Correction of DEX Infusion Volume in Section 8.3.1  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926172] MERGE/DASH at [ADDRESS_926173] ion 9.9.2  
Added Clinical Lab eGFR to Visit 6 in Schedule of 
Assessments Table Section 10  
Changed f ootnote in Section 10 to "Research and 
Clinical labs must be drawn between POD #1 -7" 
Removed Ktrans assessment to Statistical Methods 
2b in Section 16  
Amended the Glow N‚Äô Tell  tape protocol in Section 
9.5 Treated Segment Registration and 11.2 Visit 2 
Procedure  
 
1.6 12 JUN 2018  Added under subheading 5.2 Secondary Endpoints: 
5. Change in subject study status based on 
subjects receiving reintervention on < or >75% of 
treated seg ment.‚Äù  
Added subheading Section 5.4 under Completion 
Endpoints: Subject Status and Study Completion 
under Section [ADDRESS_926174] udy Completion under  
Section 11 Evaluation  By [CONTACT_683905] 13.1 Early 
Discontinuation/ Withdrawals  after Adverse Event 
an example, ‚Äú(i.e index segment restenosis or 
occlusion <30 days of index segment treatment)  
 
 
 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926175], due to safety concerns (changes 
made to List of Abbreviations, Protocol Synopsis, 
Sections 1.1, [IP_ADDRESS] , 5.1, 8.1, 9.6, 9.8, 10, 11.2, 
11.7, 11.8, 16.2, and 16.4)  
Reduction of Number of Subjects to 54 overall, 27 
per site (changes made to Protocol Synopsis, 
Section 16.4)  
Duration of Subject Part icipation has been 
extended to 36 months, with the addition of two 
telephone follow up visits (changes made to 
Protocol Synopsis, Sections 4.1, 5.4, 9.1.7, 10, 
11.8, 11.11, and 15)  
Mercator MedSystems location revised to 
Emeryville, CA (Section 1.1)  
Section 1.2 (Literature References) includes two 
new references, Nos.74 (Katsanos et. al.) & 75 
(FDA Letter from August 7th 2019)  
Section 11.11 (Study Completion) ‚Äì 1-month is 
defined as ÔÇ≥ 30 days.  ÔÇ≥75% of treated segment  
Section 16.4 (Sample Size and Rand omization) ‚Äì 
added calculations determining sample size  
 
1.[ADDRESS_926176] 2019  Section 5.2 (Secondary Endpoints) ‚Äì ‚Äú5. Change in 
subject study status based on subjects receiving 
reintervention on < 75% or ÔÇ≥ 75% of treated 
segment. ‚Äù 
Section 5.4 (Completion Endpoints) ‚Äì ‚Äú2. Subject 
develops restenosis after the 1-month study follow -
up, requiring reintervention of ÔÇ≥ 75% of treated 
segment. ‚Äù 
Section 5.4 (Completion Endpoints) ‚Äì ‚ÄúIf subject 
develops restenosis after the  1-month study follow -
up, requiring reintervention of <75%  of the treated 
segment, please see section 11. 10 for specifics on 
recording Unplanned Visits for Index Leg 
Reintervention and continuing  follow -up.‚Äù 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926177] 2019  Page 7 of 72 
 Section 11.10 (Unplanned Visit for Index Leg 
Reinterventi on) ‚Äì ‚ÄúFor further specifics on study 
completion, please see section 11. 11 Study 
Completion. ‚Äù 
Section 11.11 (Study Completion) ‚Äì ‚Äú2. Subject 
develops restenosis after the 1 -month study follow -
up, requiring reintervention of ÔÇ≥ 75% of treated 
segment. ‚Äù 
Section 11.11 (Study Completion) ‚Äì ‚ÄúIf subject 
develops restenosis after the 1 -month study follow -
up, requiring reintervention of <75% of the treated 
segment, please see section 11. 10 for specifics on 
recording Unplanned Visits for Index Leg 
Reintervention  and continuing follow -up.‚Äù 
Section 13.1 (Early Discontinuation/Withdrawal) ‚Äì 
‚Äú(i.e. treated  segment restenosis /occlusion 
occurring between index procedure date and the 1 -
month study follow -up date )‚Äù 
 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926178] 2019  Page 8 of 72 
  
Clinical Research Protocol  
INtima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic 
Resonance Imaging  
INVADER MRI  
 
Protocol Number:  1.8 
Version Date:  [ADDRESS_926179]:  none  
IND Number:  n/a 
  
Funding Organization:  National Institutes of Health  
National Heart, Lung, and Blood Institute (NHLBI)  
Principal Investigator:  [CONTACT_5627]:   David Saloner, Ph.D . 
Telephone:  [PHONE_14242]  
E-mail:   [EMAIL_13108]  
 
Approval:  
   
PI [INVESTIGATOR_38087] (Name [CONTACT_13693])   Date  
This confidential information about an investigational product is provided for the 
exclusive use of investigators of this product and is subject to recall at any time.  
The information in this document may not be disclosed unless federal or state law 
or re gulations require such disclosure.  Subject to the foregoing, this information 
may be disclosed only to those persons involved in the study who have a need to 
know, with the obligation not to further disseminate this information.   
 
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926180] read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety of the study subjects enrolled under my supervision and providing   
the University of [LOCATION_004], San Francisco Committee on Hu man Research (CHR)  with 
complete and timely information, as outlined in the protocol.  It is understood that all information 
pertaining to the study will be held strictly confidential and that this confidentiality requirement 
applies to all study staff at this site. Furthermore, on behalf of the study staff and myself, I agree 
to maintain the procedures required to carry out the study in accordance with accepted GCP 
principles and to abide by [CONTACT_38114].  
 
Protocol Number:   1.8 
Protocol Title:   INtima Versus Adventitia Drug Delivery to Elucidate 
Mechanisms of Restenosis: Magnetic Resonance Imaging  
INVADER MRI  
 
Protocol Date:   [ADDRESS_926181] 2019 
 
 
 
   
Investigator Signature   [CONTACT_428878] #  [ADDRESS_926182]. MS 114D  
 San Francisco, CA [ZIP_CODE]  
  
Phone Number  [PHONE_14242]  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926183] OF ABBREVIA TIONS  14 
PROTOCOL SYNOPSIS  16 
1 BACKGROUND  20 
1.1 Overview of Clinical Studies  ................................ ................................ ...............................  23 
1.2 Literature References  ................................ ................................ ................................ .........  28 
2 STUDY RATIONALE  34 
2.1 Risk / Benefit Assessment  ................................ ................................ ................................ .. 34 
2.1.1  Anticipated Clinical Benefits  ................................ ................................ ..............  34 
2.1.2  Anticipated Adverse Events to balloon angioplasty of the SFA  .........................  34 
2.1.3  Possible Risks of Participation in this Clinical Trial  ................................ ............  35 
3 STUDY OBJECTIVES  40 
3.1 Primary Objective  ................................ ................................ ................................ ...............  40 
3.2 Secondar y Objectives  ................................ ................................ ................................ .........  40 
4 STUDY DESIGN  40 
4.1 Study Overview  ................................ ................................ ................................ ..................  40 
4.2 Specific Aims  ................................ ................................ ................................ .......................  40 
5 STUDY ENDPOINT S 41 
5.1 Primary Endpoint  ................................ ................................ ................................ ................  41 
5.2 Secondary Endpoints  ................................ ................................ ................................ ..........  41 
5.3 Safety Endpoints  ................................ ................................ ................................ .................  41 
5.4 Completion Endpoints  ................................ ................................ ................................ ........  41 
6 SUBJEC T SELECTION  42 
6.1 Study Population  ................................ ................................ ................................ ................  42 
6.2 Inclusion Criteria ................................ ................................ ................................ .................  42 
6.3 Exclusion Criteria  ................................ ................................ ................................ ................  42 
7 CONCURRENT MEDICATIONS  43 
7.1 Allowed Medications and Tr eatments  ................................ ................................ ...............  43 
8 STUDY TREATMENTS  43 
8.1 Method of Assigning Subjects to Treatment Groups  ................................ .........................  43 
8.2 Formulation of Treatment  ................................ ................................ ................................ .. 44 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926184] 2019  Page 11 of 72 
 8.2.1  Packaging and Labeling  ................................ ................................ ......................  44 
8.3 Supply of DEX at the Site  ................................ ................................ ................................ .... 44 
8.3.1 Dosage/Dosage Regimen  ................................ ................................ ...................  [ADDRESS_926185]  ................................ ................................ ................................ ... 45 
9.1.2  Demographics  ................................ ................................ ................................ .... 45 
9.1.3  Medical History  ................................ ................................ ................................ .. 45 
9.1.4  Concomitant Medications  ................................ ................................ ..................  46 
9.1.5 Vital Signs  ................................ ................................ ................................ ...........  46 
9.1.6  Physical Examination ................................ ................................ ..........................  46 
9.1.7  Vascular Examination  ................................ ................................ .........................  46 
9.2 Laboratory Measurements  ................................ ................................ ................................ . 48 
9.2.1  Research Laboratory Measurements  ................................ ................................ . 48 
9.2.2  Clinical Laboratory Measurements  ................................ ................................ .... 48 
9.3 Adverse Events  ................................ ................................ ................................ ...................  48 
9.4 Walking Impairment Questionnaire  ................................ ................................ ...................  48 
9.5 Treated Segment Registration ................................ ................................ ............................  49 
9.6 Randomization ................................ ................................ ................................ ....................  49 
9.7 DEX Infusion  ................................ ................................ ................................ .......................  49 
9.7.1  Equipment  ................................ ................................ ................................ ..........  49 
9.8 Order of Operations  ................................ ................................ ................................ ...........  49 
9.9 Research MRI  ................................ ................................ ................................ ......................  51 
9.9.1  Equipment  ................................ ................................ ................................ ..........  51 
9.9.2  Protocol  ................................ ................................ ................................ ..............  51 
9.9.3  Pre-Reintervention MRI  ................................ ................................ .....................  53 
9.10  Clinical Ultrasound  ................................ ................................ ................................ .............  53 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926186] 2019  Page 12 of 72 
 10 SCHEDULE OF ASSESSMENTS  54 
11 EVA LUATIONS BY [CONTACT_16990]  56 
11.1  Visit 1: Screening & Baseline (Day -30 to Day -1) ................................ ...............................  56 
11.2  Visit 2: Procedure (Day 0)  ................................ ................................ ................................ ... 56 
11.3  Visit 3: Post -Operative Assessments (Day 1 -7) ................................ ................................ .. 56 
11.4  Visit 4: 1 Month Follow -up (Day 30¬±7)  ................................ ................................ ..............  57 
11.5  Visit 5: 6 Month Follow -up (Day 180¬±14)  ................................ ................................ ..........  57 
11.6  Visit 6: 12 Month Follow -up (Day 365¬±30)  ................................ ................................ ........  57 
11.7  Visit 7: 24 Month Telephone Follow -up (Day 730¬±30)  ................................ ......................  57 
11.8  Visit 8: 36 Month Telephone Follow -up (Day 1095¬±30)  ................................ ....................  58 
11.9  Early Withdrawal Visit  ................................ ................................ ................................ ........  58 
11.10  Unplanned Visit for Index Leg Reintervention  ................................ ................................ ... 58 
11.11  Study Completion  ................................ ................................ ................................ ...............  59 
12 ADVERSE EVENT REPORTING AND DOCUMENTATION  59 
12.1  Adverse Events  ................................ ................................ ................................ ...................  59 
12.2  Serious A dverse Events (SAE)  ................................ ................................ .............................  60 
12.2.1  Serious Adverse Event Reporting  ................................ ................................ .......  60 
13 DISCONTINUATION AND REPLACEMENT OF SUBJECTS  60 
13.1  Early Discontinuation/Withdrawal  ................................ ................................ .....................  [ADDRESS_926187] Confidentiality  ................................ ................................ ................................ .......  66 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926188] 2019  Page 13 of 72 
 18 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS  66 
18.1  Protocol Amendments  ................................ ................................ ................................ .......  66 
18.2  Institutional Review Boards and Independent Ethics Committees  ................................ ... 66 
18.3  Informed Consent Form  ................................ ................................ ................................ ..... 67 
18.4  Publications  ................................ ................................ ................................ ........................  67 
18.5  Investigator Responsibilities ................................ ................................ ...............................  67 
APPENDIX 1.  SAMPLE COLLECTION & PROCESSING GUIDELINES  [ADDRESS_926189] ADMIRAL DCB CATHETER IFU  72 
APPENDIX 8. STELLAREX DCB CATHETER IFU  72 
APPENDIX 9. WALKING IMPAIRMENT QUESTIONNAIRE (WIQ)  72 
 
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926190]  
ITT Intention -To-Treat  
LRNC  Lipid Rich Necrotic Core  
LV Lumen Volume  
MCP -1 Monocyte Chemo tactic Protein 1 
MERGE  Motion sensitized driven Equilibrium prepared Rapid Gradient Echo  
MRA  Magnetic Resonance Angiogram  
MRI Magnetic Resonance Imaging  
NIH National Institutes of Health  
NHLBI  National Heart, Lung, and Blood Institute  
NSF Nephrogenic Systemic Fibrosis  
OSI Oscillatory Shear Stress  
PI [INVESTIGATOR_683873]#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926191] 2019  Page 15 of 72 
 PWA  Percent Wall Area  
PTX Paclitaxel  
PWV  Percent Wall Volume  
SAE Serious Adverse Event  
SFA Superficial Femoral Artery  
SMC  Smooth Muscle Cell  
TOF Time -of-Flight  
TVA Total Vessel Area  
TVV Total Vessel Volume  
WA Wall Area  
WV Wall Volume  
WIQ Walking Impairment Questionnaire  
WSS  Wall Shear Stress  
WSS G Wall Shear Stress Gradient  
  
 
 
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926192] 2019  Page 16 of 72 
 PROTOCOL  SYNOPSIS  
TITLE  INtima Versus Adventitia Drug Delivery to Elucidate Mechanisms of 
Restenosis: Magnetic Resonance Imaging (INVADER MRI)  
  SPONSOR  National Institutes of Health  
National Heart, Lung, and Blood Institute (NIH NHLBI)  
  FUNDING 
ORGANIZATION  NIH NHLBI  
NUMBER OF SITES  2 
  RATIONALE  Peripheral artery disease (PAD) affects at least [ADDRESS_926193] 
blockages in the leg arteries, even after these procedures.  
 
Advances in Magnetic resonance imaging (MRI) offer promise for 
understanding the mechanism of failure through insights into vessel 
wall composition , remodeling,  and inflammation . Restenosis has a 
known relationship to inflammation. Advances in micro -catheter  
technologies offe r the ability to deliver  anti-inflammatory medications 
such as dexamethasone (DEX)  directly to the adventitia .  
 
This study aims to investigate if patient -specific parameters affect 
angioplasty out comes, if DEX has a biological effect on the vessel 
wall, and if this effect is through the reduction of inflammation.  
  STUDY DESIGN  Prospective, multi -center randomized  Phase IV trial. 
  PRIMARY OBJECTIVE  The primary objective is to assess the mechanism s of vascular 
healing following balloon angioplasty treatment to stenotic arteries 
from atherosclerosis.  Vascular healing will be assessed by [CONTACT_683906] (PWV) from [ADDRESS_926194] -
angioplasty to 12 months  
 
  SECONDARY 
OBJECTIVES  1. To determine whether DEX infusion will result in less 
inflammation as measured by [CONTACT_41225] (MCP -1, CRP, and IL -1Œ≤) 
and tissue imaging ( Ktrans) markers of inflammation  
2. To determine whether patient -specific physiological factors 
correlate w ith vascular healing  
  NUMBER OF 
SUBJECTS  54 overall  
27 per site  
  
    
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926195] SELECTION  
CRITERIA  Screening Inclusion Criteria : 
1. Male or non -pregnant female ‚â• [ADDRESS_926196] Clinical Category 2 -6 
4. Stenosis detected by [CONTACT_683907] ‚Äôs opi[INVESTIGATOR_683874] s 
5. Patient is willing to provide informed consent and comply with 
the required follow up visits, testing schedule, and medication 
regimen  
6. eGFR ‚â• 30 and/or  threshold established by [CONTACT_683908] : 
1. De novo atherosclerotic lesion qualifying for angioplasty  
2. A patent artery proximal to the index lesion. Concomitant 
inflow procedur es, including open femoral artery 
endarterectomy and/or  stenting of the iliac arteries, are 
permissible.  
3. >50% diameter stenosis of the superficial femoral artery 
and/or popliteal artery (between the profunda and 
tibioperoneal trunk)  
4. Reference vessel diame ter ‚â•3 mm and ‚â§ 8mm  
5. Successful wire crossing of lesion  
6. Successful angioplasty of the index  lesion or part of the index 
lesion , defined as ‚â§30% residual lumen stenosis compared 
with adjacent non -diseased lumen diameter, without flow -
limiting dissection  
 
Screening Exclusion Criteria : 
1. Any contraindication to receiving an MRI  
2. Pregnant, nursing, or planning on becoming pregnant in < 
2yrs 
3. Life expectancy of < 1 yr 
4. History of solid organ transplantation  
5. Patient actively participating in another investigational device 
or drug study  
6. History of hemorrhagic stroke within 3 months  of index 
procedure  
7. Previous or planned surgical or interventional procedure 
within 30 days of index procedure  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926197] 2019  Page 18 of 72 
 8. Chronic renal insufficiency with eGFR < [ADDRESS_926198] media, gadoliniu m, aspi[INVESTIGATOR_683875]  
12. Systemi c fungal infection  
13. Acute limb ischemia  
14. Prior participation of the index limb in the current study 
(contralateral treatment is allowed)  
15. Patient is being treated with long-term steroids  (not including  
treatment of a bronchial condition with inhaled steroids ) 
Procedural Exclusion Criteria : 
1. Index l esions extending into the tibial trifurcation or above the 
profunda. Note: the outflow tibial artery can be treated 
concomitantly. Similarly, the common femoral artery can be 
treated concomitantly, either with open en darterectomy and 
patch angioplasty or with endovascular methods.  However, 
the index lesion cannot be contiguous with either the CFA or 
the tibial trifurcation.  
2. Circumferential calcification at index lesion, which in the 
judgment of the investigator wo uld prevent penetration of the 
Micro-Infusion catheter needle through the vessel wall  
3. Inadequate distal outflow defined as no patent tibial arteries  
(>50% stenosis).  The outflow vessel can be established at 
the time of primary treatment  
4. Use of adjunctive therapi[INVESTIGATOR_683876]. Chocolate 
balloons and/or scoring balloons are allowed, if used below 
reference diameter.  
      DURATION OF 
SUBJECT 
PARTICIPATION AND 
DURATION OF STUDY  Subjects will be on study for up to 36 months  
Screening:  up to 30  days  
Follow -up:  [ADDRESS_926199] follow -
up, and six months for final data clean -up.  
E    PRIMARY ENDPOINT  The primary endpoint for this study will be percent wall volume (PWV) 
change of the treated segment  from the [ADDRESS_926200] -intervention 
MRI scan to 12 months between DEX  treated and non-DEX (PTX or 
POBA)  treated patients.  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926201] 2019  Page 19 of 72 
 The treated segment is defined as t he length of vessel, 
encompassing  the index lesion , that has undergone primary 
revascularization, from normal back to normal artery.  
  STATISTICS  
Primary Analysis Plan  The primary analysis will be an intention -to-treat (ITT) comparison of 
observed change in mean ŒîPWV between treatment groups at [ADDRESS_926202]. Because ŒîPWV may be nonlinear in time, 
linear splines with knots at 24 hours, 1 month, 6 months,  and 12 
months will be used to fit the model.  
Multivariable regression models will be constructed to determine 
independent variables associated with ŒîPWV controlling for 
demographic and anatomical variables, statin use, inflammatory 
markers, and smoking.  
We will also investigate effects by [CONTACT_683909], clinical, and 
anatomic variables. Predictors of PWV will be evaluated via 
univariate and multivariate regression analysis.  
Rationale for Number 
of Subjects  The sample size for  this study is based on the statistical hypothesis 
for the primary endpoint, observed change in mean ŒîPWV between 
groups at 12 months.  
While there are no predicate serial studies of PWV changes in 
femoral artery restenosis following angioplasty to estimat e the 
sample size, previous work on the progression of de novo 
atherosclerosis in similar sized peripheral arteries (carotids) forms the 
basis of this  estimation.  
Based on the power calculations outlined in  Sec 16.[ADDRESS_926203] a 2.7% 
difference in PWV at a power level of 80%.  
Assigning a 20% attrition rate due to loss to follow up and/or index  
lesion revascularization, [ADDRESS_926204] at a 5% significance level.  
 
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926205] 2019  Page 20 of 72 
 1 BACKGROUND  
 
Population to be studied  
This is a randomized trial designed to explore the mechanisms of restenosis following balloon 
angioplasty.  This trial will evaluate subjects with peripheral artery disease who require an 
endovascular intervention of the femoropopliteal arterial segment (SFA/Popliteal)  to restore 
blood flow to the leg. Peripheral artery disease (PAD) is a condition defined by [CONTACT_683910] . The SFA is the most common peripheral 
artery affected in patients with PAD and percutaneous transluminal angioplasty (PTA) is the 
most common mode of treatment. PTA may be used alone or in combination with another 
treatment modality such as a stent or debulking device but it serves as the primary treatment 
platform for restoring blood flow to the leg. There is an estimat ed 800,000 SFA procedures 
performed worldwide annually, representing a market of approximately $1.5 billion. Roughly 
450,000 of those cases are performed in the [LOCATION_002] with an overall market growth 
estimated in the mid -single digits.  
 
The Current T reatment of PAD and the Epi[INVESTIGATOR_683877] (PTA) is the cornerstone of endovascular treatment of arteries.   A balloon is 
used to deploy , or used for post -dilation of,  vascular stents (balloon expandable).  PTA is also 
used in conjunc tion with debulking therapy. However, u ntil recently PTA was rarely used as a 
single modality to treat arterial stenosis  except in the short lesions, (TASC II A, < 5 cm), due to 
the high rate of binary restenosis 67% (primary patency 33%, Krisna Rocha Sing h). This high 
rate of failure for PTA was also noted in the control arm of the Zilver PTX study which evaluated 
a paclitaxel covered stent compared to  balloon angioplasty  alone .   More recently, better PTA 
techniques ha ve resulted in  decreased restenosis rates of PTA to about 50%.  This 
improvement occurred as a result of 1) sequential dilation of the stenosis with progressively  
larger balloons, 2) slower inflation of each balloon  to reach nominal dilation, and 3) longer 
inflation times of each balloon at nominal pressure often exceeding 2 minutes, and limiting the 
inflation atmospheres and barotrauma.   Further improvement was attained by [CONTACT_1583] a 
proprietary matrix to the balloon surface to allow paclitaxel  (PTX)  to be delivered into the artery 
wall.  These are known as drug -coated balloons (DCB) and there are 3 approved by [CONTACT_1622]: 
the INPACT Admiral DCB (Medtronic Inc, Minneapolis MN), the Lutonix 035 DCB (C. R. Bard 
Inc, Covington GA) and the Stellarex DCB (Spectranetics Corp, Colorado Springs CO).  In 
general, the effectiveness and safety profiles of these devices are not substantially 
different. Primary patency rates in selected lesions can approach 75% with these devices 
under trial conditions (<10cm lesions, claudication pati ents) and they are reported to attain 
clinically -driven target lesion revascularization (cd -TLR), similar to stents.  One concern about 
DCBs is that the depot drug delivery is at the intima surface.  To reach the deeper layers of the 
arterial wall the drug  must diffuse down its concentration gradient in accordance with Fick‚Äôs Law  
ùúïÔÅ™
ùúïùë°=-DÔÉë2ÔÅ™, where ùúïÔÅ™
ùúïùë° is the diffusion flux, D is the diffusion coefficient, ÔÉë2 is the Laplacian 
operator, and ÔÅ™ is the amount if drug in dimensions mol/mm3. ÔÅ™=ÔÅ™(x,t) is a function which 
depends on location  x and time,  t, in seconds. Therefore, the initial concentration of the drug will 
be highest in the intima until , over time, the drug diffuse s evenly through the vessel wall. This 
potentially could inhibit re -endothelialization of the treated area and cause increased restenosis 
after the drug is no longer retained in the wall.  This would be referred to as late catch up where 
the treatment arm would catch up to the  control arm after a specified period of time.  In the 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926206] been known to cause late stent thrombosis 
due to delinquent endothelialization over the stent struts.  This phenomenon  necessitates 
prolonged dual ant iplatelet therapy (DAPT) . Because of these reasons and others, as will be 
explained below, the adventitia is an alternative to the intima in drug delivery.     
It is desirable to avoid stents in leg arteries if possible as vascular stents are susceptible to 
micro -abrasion, friction, and fatigue.1 Constant micro -forces associated with daily ambulation 
lead to stent fractures and restenosis. Once restenosis occurs within a stent, it is very difficult to 
regain and maintain patency of the artery.2 Further, future therapy options such as by[CONTACT_683911] ‚Äúburn bridges‚Äù for 
future revascularization options. In fact, more by[CONTACT_683912] r de novo lesions, and studies show that by[CONTACT_683913].3 This truly is an epi[INVESTIGATOR_683878].4  
  
The Tunica Adventitia is an Active Participant in Arterial Restenosis  
Once thought to be a passive la yer of the arterial wall, the tunica adventitia is now known to be 
extremely metabolically active and capable of regulating vascular hemostasis.8, 9 The adventitia 
contains a rich variety of immune cells, including T cells, B cells, dendritic cells, progen itor cells, 
and fibroblasts that can differentiate into myofibroblasts.10-13 There is extensive microvascular 
architecture, which can traffic inflammatory cells into the vessel wall following injury.14 Balloon 
angioplasty experiments in pig coronary arteri es demonstrate that the adventitia is the primary 
site for acute inflammation after mechanical vascular injury.15 The hypothesis that these cells 
contribute to intimal hyperplasia and restenosis is supported by [CONTACT_683914]. In porc ine models of angioplasty, injections with 5 -bromo -2-deoxyuridine (BrDU) have 
identified proliferating cells located in the adventitia as early as two days following injury which 
appear to migrate into the inner vessel in subsequent time points.16, [ADDRESS_926207] migration into the media and intima following balloon injury.20 Collectively, these 
studies support an ‚Äúoutside -in‚Äù hypothesis of vascular inflammation and provide important 
biologica l rationale to target the adventitia to reduce restenosis.  
 
Restenosis is an Inflammatory Process  
Balloon angioplasty produces a barotraum atic (8-15 atmospheres) mechanical injury, resulting 
in stress signals and homing of inflammatory cells into the artery.15, 21, [ADDRESS_926208] shown in a 
porcine balloon injury model that inflammatory cells peak in the adventitia early after injury and 
then slowly decline over the next 28 days.23 P-selectin and vascular cell adhesion molecule -1 
(VCAM -1) is up -regulated i n vasa vasorum endothelial cells soon after balloon injury thus 
providing a means for increased inflammatory cell trafficking.[ADDRESS_926209] at endothelial junctions is either incomplete or absent in 76% of the 
vessels.24, 30, [ADDRESS_926210] techniques  with kinetic modeling can measure adventitial perfusion 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926211] 2019  Page 22 of 72 
 which is a function of both the permeability and the surface area of the adventitial vascu lature . 
This highly validated technology forms the basis of in vivo assessment of vascular inflammation 
and t he therapeutic response of mitigating drugs.  
  
Glucocorticoid Receptor as a Therapeutic Target for Vascular Injury  
The glucocorticoid receptor (GR) is a member of the nuclear hormone receptor superfamily of 
ligand -activated transcription factors. Activatio n of GR results in binding of receptor homodimers 
to glucocorticoid response elements in target genes, leading to initiation or repression of 
transcription. Cortisol is the naturally occurring ligand to the GR and unbound fraction of cortisol 
can diffuse t hrough the cell wall to interact with the cytosolic receptor. DEX is a synthetic 
glucocorticoid with [ADDRESS_926212] demonstrated 
that DEX down -regulates monocyte chemoattractant protein -1 (MCP -1), tumor necrosis factor Œ± 
(TNF -Œ±), and interleukin 1Œ≤ in nano - and micromolar concentrations in vascular SMCs.35, [ADDRESS_926213] growth factor in vascular 
SMCs. Intra -muscular DEX treatment demonstrated decreased macrophages present in 
atherosclerotic lesions and inhibition of macrophage accumulation follo wing balloon angioplasty 
in cholesterol fed rabbits.37 DEX has been shown to inhibit the proliferation and migration of 
smooth muscle and inflammatory cells as well as adventitial myofibroblasts through effects on 
thymidine kinase, matrix metalloproteinase s, and retinoblastoma protein.38-40 DEX inhibits the 
autocrine induction of PDGF -Œ± chains ‚Äì a known potent SMC mitogen. DEX induces the anti -
inflammatory proteins annexin 1 and mitogen activated kinase phosphatase 1, while repressing 
the transcription of p ro-inflammatory molecules such as cyclooxygenase 2.32 DEX also markedly 
inhibits the production of ROS by [CONTACT_683915]. DEX increases the immune -
modulatory cytokine IL -10, which is known to inhibit the pro -inflammatory TH1 cells.41 DEX also 
inhibits collagen production and extracellular matrix synthesis, which is responsible for late 
lumen loss following PTA42, 43 and thought to be due to negative (shrinkage) arterial 
remodeling.[ADDRESS_926214] -
intervention compared to patients treated with a bare metal stent.46, 47 Two coronary studies 
independently  tested the use of the BiodivYsio Matrix Lo stent loaded with DEX versus the 
same stent platform without drug as control. Han et al. randomly assigned a total of 92 patients 
to the DEX or control group.48 The use of DEX -eluting stents was the only independ ent predictor 
for the major adverse cardiac event at 12 months (relative risk 0.20, 95% CI 0.06 -0.68, P = 
.009) and binary restenosis at 6 months (relative risk 0.17, 95% CI 0.05 -0.60, P = .006) by 
[CONTACT_104795]. In a similar study, Konig et al. ra ndomly assigned 120 patients with acute 
coronary syndrome to revascularization using the Dexamet stent or BMS.49 The target lesion 
revascularization rate was lower in the Dexamet group (16.67% vs 33.33% patients; P = .031) 
and angiography revealed improved  lumen restoration in the Dexamet stent group (late lumen 
loss, 0.55 ¬± 0.65 vs. 1.07 ¬± 0.92 mm P = .001).  
 
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926215] 2019  Page 23 of 72 
 1.1 Overview of Clinical Studies  
 
Pharmacokinetic Studies of Dexamethas one In Porcine Carotid Arteries  
The DEX pharmacokinetic (PK) profile has been demonstrated in a study of the M icro-Infusion 
catheter delivery into the adventitial tissue of porcine carotid arteries, Figure 1. In this study, 
therapeutic levels in the range of [ADDRESS_926216] duration of the therapeutic window to treat vascular inflammation is unknown, 
based on preclinical PTA models, the optimal time frame is 7 -30 days. This is supported by 
[CONTACT_683916],23 where it was 
determined that the adventitial leukocyte infiltration is decreased by 60% of peak value within [ADDRESS_926217] -in-man safety and feasibility study of DEX delivery to femoral and 
popliteal adve ntitia (NCT 01507558) with the B ullfrog Micro-Infusion
 catheter (Mercator 
MedSystems, Emeryville , CA).7 Patients with SFA stenosis or occlusions up to 15 cm were 
eligible for this study. Mean lesion length was 8.9¬±5.3 cm, N=20 with 80% located in the distal 
SFA/popliteal artery, which has traditionally been considered a no stent zone. The mean 
number of inf usions required to completely treat each lesion was 3.0 ¬± 1.3, minimum 1 and 
maximum 6. The mean volume injected was 3.8 ¬± 1.9 ml which contained a mean of 12.1 ¬± 6.1 

CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926218] 2019  Page 24 of 72 
 mg of DEX and .80 ¬± .[ADDRESS_926219]. This equated to a mean of 1.6 ¬± 1.1 mg of DEX per 
centimeter of lesion length. The minimal dose was 3.2 mg and the maximal dose a patient 
received was 24 mg of DEX. Accordingly,  there was a positive linear correlation between the 
amount of DEX received and length of lesion treated, R2=.27, P=.019.  
Proced ural safety was seen in 100% of patients, with a lack of drug -related or device -related 
serious adverse events or major adverse limb events within 30 days of the procedure. At the 6 
month follow up, two subjects had experienced a target lesion restenosis, as defined by a peak 
systolic velocity ratio (PSV lesion /PSV reference ) > 2.4 or occlusion noted by [CONTACT_683917] a 
90% patency rate. The ankle -brachial index improved from 0.67 ¬± 0.17 pre -op to 0.88 ¬± 0.18 at 
6 months (P<0.003) and Rutherford classificatio n scores decreased from 3.1 ¬±. 71 to 0.5 ¬± .70, 
p<.001 indicating improved hemodynamic and clinical benefit with DEX.  
 
Update on the DANCE single arm multi -institutional study  
 
Figure 3 . Data from the ongoing DANCE trial.  Baseline and 24 hours blood markers of 
inflammation were built in as a surrogate endpoint.  From left to right, Schill inger CRP levels in 
patients undergoing peripheral artery endovascular treatment, data generated from  the DANCE -
Pi[INVESTIGATOR_2268], and DANCE PTA and DANCE ATX arms.  CRP - C reactive protein, ATX -atherectomy  
 
Markers of technical success u sing the M icro-Infusion catheter  
The M icro-Infusion catheter (Mercator MedSystems, Emeryville , CA), a FDA 510K -cleared 
device, is a  rapid - exchange, wire -guided catheter with a balloon -sheathed 1.5 mm long, 35 -
gauge (140 Œºm diameter) needle that delivers infusions to adventitial and perivascular tissues. 
Using standard angioplasty inflation equipment, the balloon is inflated exposing the needle. 
When the balloon contacts the arterial wall opposite the needle tip, contact [CONTACT_683918].  
 

CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926220] along the artery wall. A 
.014 wire can be seen within the lumen of the artery and the 
Glow ‚ÄòN T ell tape provides a reference. After about three 
minutes,  further longitudinal diffusion within the adventitia 
obscures the border between the separate infusions.  
 
The contact [CONTACT_683919] [ADDRESS_926221] (4:1) is then delivered under fluoroscopic guidance at a rate of 1 ml/min to the 
adventitia and perivascular tissues. When the infusion is complete, the balloon is deflated, 
sheathing the needle, and allowing the catheter to be withdrawn. The drug contrast admixture 
can be seen as ‚Äústaining‚Äù along the blood vessel providing visual confirmation of su ccessful 
drug delivery, Figure 4  (left). It is our experience that a single injection produces 360¬∞ delivery of 
drug around the circumference of the vessel coverage and extends approximately [ADDRESS_926222] be carried out with an FDA -approved DCB balloon  catheter for 
treatment of arteries and veins according to the manufacturer‚Äôs instructions for us e. The 
INPACT SFA, LEVANT 2 , ILLUMENATE PI[INVESTIGATOR_683879] (IDE) safety and effectiveness trials.   
The LEVANT 2 study was a prospective, multicenter, single -blind, randomized, safety and 
efficacy study which randomized in a 2:[ADDRESS_926223] 2 and 3 patients.  Freedom from 
the primary safety endpoint  (composite all cause 30 day death, device related death at 365 
days, index limb amputation, target vessel revascularization)  evaluated graphically by [CONTACT_5263] -
Meier analysis (ITT) was 86.7% in the test DCB arm and 81.5% in the control arm.  The primary 
effectiveness endpoint was freedom from binary restenosis or target lesion revascularization 
was 73.5% in the DCB text arm and 56.8%  in the control arm.   
 

CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926224] SFA study was a multicenter, single -blind, randomized controlled safety and 
efficacy study with a 2:[ADDRESS_926225] 
DCB and 111 subjects treated with POBA. Randomization occurred once the les ion was 
crossed and successful initial balloon angioplasty was performed.  It is not known how many 
subjects were excluded due to unsuccessful balloon angioplasty. Freedom from the primary 
safety endpoint, freedom from device or procedural related death at  30 days or index limb 
amputation or target vessel revascularization, occurred in 95.6% in the test DCB group and 
76.6% in the control group.  Primary patency was 78.4% in the DCB test group a nd 49.5% in the 
control group. Although the subject was blinded to the treatment provided, the local research 
team was not. All primary endpoint events were adjudicated by a core laboratory and Clinical 
Events Committee, both of whom were blinded to the treatment provided.  
 
The ILLLUMENATE PI[INVESTIGATOR_683880] a m ulticenter, single -blind, randomized controlled 
safety and efficacy study with a 2:[ADDRESS_926226] was blinded to the treatment 
provided, the local research team was not. All primary endpoint events were adjudicated by a 
core labo ratory and Clinical Events Committee, both of whom were blinded to the treatment 
provided. Freedom from the primary safety endpoint (composite of 30 -day freedom from device 
and procedure -related death and 1 year freedom from target limb major amputation an d CD -
TLR) was 92.1% in the DCB group and 83.2% in the control group. Freedom from primary 
effectiveness endpoint (restenosis or CD -TLR at 1 year) was 76.3% in the DCB group and 
57.6% in the control group.  
 
All DCBs lose paclitaxel during the delivery and i nflation of the balloon. The ILLLUMENATE 
PI[INVESTIGATOR_683881] a [ADDRESS_926227] or Lutonix DCBs, there was 
measurable paclitaxel in the downstream (non -target) tissues at [ADDRESS_926228] DCB. In addition, embolized ‚Äúcrystalline -like material‚Äù was 
seen in the downstream tissue after treatment with INPACT but not Lut onix DCB.  
 
In December 2018, a meta -analysis of published randomized clinical trials demonstrated a 
significantly increased late (3 -5 year) mortality rate in subjects treated with paclitaxel -coated 
devices for femoropopliteal peripheral artery disease. In response to this meta -analysis, the 
FDA has issued 3 letters advising health care practitioners and convened a "public meeting of 
the Circulatory System Devices Panel of the Medical Devices Advisory Committee" from June 
19-20, 2019. An FDA "Letter to Healt hcare Providers" from August 9, 2019 summarized the 
FDA's analysis of available trial data with the conclusion that "the crude mortality rate at 5 years 
was 19.8% (range 15.9% - 23.4%) in patients treated with paclitaxel -coated devices compared 
to 12.7% (r ange 11.2% - 14.0%) in subjects treated with uncoated devices. The relative risk for 
increased mortality at 5 years was 1.57 (95% confidence interval 1.16 ‚Äì 2.13), which 
corresponds to a 57% relative increase in mortality in patients treated with paclitaxe l-coated 
devices. A meta -analysis performed by [CONTACT_683920] (Vascular InterVentional Advances) Physicians of 
patient -level data provided by [CONTACT_683921] a hazard ratio of 1.38 
(95% confidence interval 1.06 - 1.80)."  
 
 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926229] -enhanced MRI (DCE -MRI) with kinetic modeling to study 
adventitial perfusion, which generates physiological parameters of vasa vasorum.[ADDRESS_926230] shown in a porcine balloon injury mod el that 
microvessels were associated with restenosis.23 In validation studies in individuals with carotid 
stenosis, Ktrans was positively and significantly correlated with plasma CRP, thus providing an in 
vivo link between vascular wall inflammation and a blood marker of inflammation. Human 
validation histologic studies were also completed in patients having DCE -MRI scans prio r to 
carotid endarterectomy. These studies demonstrated correlation of Ktrans and endarterectomy 
specimen neovasculature (R=0.41, P=.04) and macrophages (R=0.49, P=.01) supplied by [CONTACT_683922].[ADDRESS_926231] of drugs on the 
vascular wall. In a study evaluating the effects of intensive lipid therapy targeting low density 
lipoprotein to below 60 mg/dl in subjects with extant cardiovascular disease, there were 
significant differences in adventit ial Ktrans at 12 months after lipid therapy (0.067 ¬± 0.028 min-1) 
compared with baseline (0.085 ¬± 0.037 min-1, p=.02).  
 
 
Figure 5 . Left: Kinetic analysis of dynamic contrast enhanced MRI of carotid atherosclerosis 
yields a parametric image ‚Äúvasa vasorum‚Äù displaying the value of fractional blood volume (ŒΩ p) in 
red and transfer constant ( Ktrans) in green. The rapid transfer in the vessel adventitia is indicated 
using yellow arrows. Right:  Image is derived from kinetic modeling of changing intensity in serial 
images coinciding with contrast agent.  
 
Computational Fluid Dynamics  
Balloon angioplasty induces barotrauma (8 -16 atmospheres) to the artery to redistribute the 
arterial wall mass, expand the arterial volume, with the goal to increase the lumen volume of the 
treated segment. This results in luminal irregularities, dissections, and residual stenosis within 
the artery. We propose that the resulting flow disturbances and shear stress gradients 
predispose to areas of restenosis due to increased wall thickening or negative remodeling. 
Surprisingly, there has been relatively little attention given to serial changes in blood flow and 
shear stress following angioplasty in the leg. CFD methodologies d eveloped by [CONTACT_683923]#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926232] conducted serial CFD -derived flow analysis 
that was carried out at three time points: [ADDRESS_926233] enhanced time -of-flight (TOF)  magnetic resonance angiogram 
(MRA ) datasets were used to acquire patient -specific geometries at each time point. Phase 
contrast magnetic resonance v elocimetry (PC -MRV) measurements were obtained at each 
imaging session and used to prescribe time - dependent velocity boundary conditions for the 
computational models. CFD simulations were carried out using the methodology described 
below. Velocity fields and wall shear stress (WSS) distributions obtained at each time point were 
then compared. The c omputational results in Figure 5  show that the size of the vessels 
increased and the WSS values substantially reduced with the maturation of the fistula.  
 
Plaqu e compositional analysis and arterial remodeling assessment with MRI  
It is unlikely that one specific type of therapy will be suited for every SFA plaque type. For 
example, Derksen et al. determined that femoral plaques with more fibrous tissue had higher 
rates of restenosis. Therefore, knowledge of plaque composition and adventitial perfusion by 
[CONTACT_683924]. MRI has been shown to provide an accurate virtual 
histological map of vascular plaques in femoral and carotid arteri es based on pi[INVESTIGATOR_534982] (see section below) using multicontrast MRI.57,[ADDRESS_926234] matched 
carotid endarterectomy histology sections via landmarks to MRI images obtained in vivo prior to 
surgery to ascertain the sensitivity and specificity of MRI tissue characterization.59,60 For plaques 
> 2 mm2, in vivo assessment of plaque composition can be accomplished with high sensitivity 
(79% to 95%) and moderate to high specificity (76% to 91%).[ADDRESS_926235] to total vessel area. 
The interclass correlation coefficient (ICC) for lipid rich necrotic core (LRNC), calcification, and 
fibrous tissue was between .88 and .95.62,63 In this applicatio n, we will characterize SFA plaque 
composition and associate each with response to DEX  or PTX (control)  treatment.  
1.2 Literature References  
1. Tzafriri AR, Vukmirovic N, Kolachalama VB, Astafieva I, Edelman ER. Lesion complexity 
determines arterial drug distrib ution after local drug delivery. J Con trol Release. 
2010;142:[ADDRESS_926236] of restenosis after femoropopliteal stenting. Journal of the 
American College of Cardiology . 2012;59:16 -23  
3. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower extremity 
by[CONTACT_4897], endovascular interventions, and major amputations. J Vasc Surg . 
2009;50:54 -60  
4. Owens CD. Commentary: Is the drug-eluting balloon the answer to the epi[INVESTIGATOR_683882]? Journal of endovascular therapy : an official journal of the International Society 
of Endovascular Specialists . 2014;21:22 -24  
5. Walker JP, Owens CD. Current status of drug -eluting stents and dru g-eluting balloons for 
the superficial femoral artery. Curr Surg Rep . 2013;1:90 -97  
6. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, 
Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during  
angioplasty of the leg. N Engl J Med . 2008;358:689 -699  
7. Owens CD, Gasper WJ, Walker JP, Alley HF, Conte MS, Grenon SM. Safety and feasibility 
of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery 
following endovascular rev ascularization. Journal of vascular surgery . 2014;59:1016 -1024  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926237] 2019  Page 29 of 72 
 8. Stenmark KR, Yeager ME, El Kasmi KC, Nozik -Grayck E, Gerasimovskaya EV, Li M, Riddle 
SR, Frid MG. The adventitia: Essential regulator of vascular wall structure and function. 
Annual review of physiology . 2013;75:23 -47  
9. Maiellaro K, Taylor WR. The role of the adventitia in vascular inflammation. Cardiovasc Res . 
2007;75:640 -648  
10. Campbell KA, Lipi[INVESTIGATOR_256794], Doran AC, Skaflen MD, Fuster V, McNamara CA. Lymphocytes 
and the adventitial immune response in atherosclerosis. Circulation research . 2012;110:889 -
900  
11. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte re cruitment 
into the aortic wall before and during development of atherosclerosis is partially l -selectin 
dependent. The Journal of experimental medicine . 2006;203:1273 -1282  
12. Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventitial 
infiltrates associated with advanced atherosclerotic plaques: Structural organization 
suggests generation of local humoral immune responses. The Journal of pathology . 
2001;193:263 -269  
13. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, Xu Q. Abundant progenitor cells 
in the adventitia contribute to atherosclerosis of vein grafts in apoe -deficient mice. The 
Journal of clinical investigation . 2004;113:1258 -1265  
14. Mulligan -Kehoe MJ, Simons M. Vasa vasorum in normal and diseased arteries. Circulation . 
2014; 129:2557 -2566  
15. Okamoto E, Couse T, De Leon H, Vinten -Johansen J, Goodman RB, Scott NA, Wilcox JN. 
Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation . 
2001;104:2228 -2235  
16. Scott NA, Cipolla GD, Ross CE, Dunn B, Mart in FH, Simonet L, Wilcox JN. Identification of a 
potential role for the adventitia in vascular lesion formation after balloon overstretch injury of 
porcine coronary arteries. Circulation . 1996;93:2178 -2187  
17. Wilcox JN, Waksman R, King SB, Scott NA. The role  of the adventitia in the arterial 
response to angioplasty: The effect of intravascular radiation. Int J Radiat Oncol Biol Phys . 
1996;36:789 -796  
18. Shi Y, O'Brien JE, Jr., Ala -Kokko L, Chung W, Mannion JD, Zalewski A. Origin of 
extracellular matrix synthesis  during coronary repair. Circulation . 1997;95:997 -1006  
19. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts 
contribute to neointimal formation in injured porcine coronary arteries. Circulation . 
1996;94:[ADDRESS_926238]. Migration of adventitial myofibroblasts 
following vascular balloon injury: Insights from in vivo gene transfer to rat carotid arteries. 
Cardiovasc Res . 2003;59:212 -221  
21. Wilcox JN, Okamoto EI, Nakahara KI, Vinten -Johansen J . Perivascular responses after 
angioplasty which may contribute to postangioplasty restenosis: A role for circulating 
myofibroblast precursors? Ann N Y Acad Sci . 2001;947:68 -90; dicussion 90 -62  
22. Ross R. Atherosclerosis --an inflammatory disease. N Engl J Me d. 1999;340:[ADDRESS_926239] K, Owens CD. Adventitial nab -
rapamycin injection reduces porcine femoral artery luminal stenosis induced by [CONTACT_683925]. Circulation. 
Cardiovascular interventions . 2013;6:701 - 709  
24. Kolodgie FD, Narula J, Yuan C, Burke AP, Finn AV, Virmani R. Elimination of 
neoangiogenesis for plaque stabilization: Is there a role for local drug therapy? Journal of 
the American Co llege of Cardiology . 2007;49:2093 -2101  
25. Langheinrich AC, Sedding DG, Kampschulte M, Moritz R, Wilhelm J, Haberbosch WG, 
Ritman EL, Bohle RM. 3 -deazaadenosine inhibits vasa vasorum neovascularization in 
aortas of apoe( -/-)/ldl(-/-) double knockout mice. Atherosclerosis . 2009;202:103 -110  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926240] 2019  Page 30 of 72 
 26. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla -Herttuala S, Ferrara N, 
Martin JF, Zachary I, Simons M. Angiogenesis -dependent and independent phases of 
intimal hyperplasia. Circulation . 2004;110:[ADDRESS_926241], Schwartz RS. Adventitial vasa vasorum in balloon -injured coronary arteries: 
Visualization and quantitation by a microscopic three -dimensional computed tomography 
technique. Journal of the American Colleg e of Cardiology . 1998;32:[ADDRESS_926242], Jr., Schwartz RS, Lerman A. 
Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. 
The Journal of clinical investigation . 1998;101:1 551-1556  
29. Cheema AN, Hong T, Nili N, Segev A, Moffat JG, Lipson KE, Howlett AR, Holdsworth DW, 
Cole MJ, Qiang B, Kolodgie F, Virmani R, Stewart DJ, Strauss BH. Adventitial microvessel 
formation after coronary stenting and the effects of su11218, a tyrosine  kinase inhibitor. 
Journal of the American College of Cardiology . 2006;47:1067 -1075  
30. Sluimer JC, Kolodgie FD, Bijnens AP, Maxfield K, Pacheco E, Kutys B, Duimel H, Frederik 
PM, van Hinsbergh VW, Virmani R, Daemen MJ. Thin -walled microvessels in human 
coron ary atherosclerotic plaques show incomplete endothelial junctions relevance of 
compromised structural integrity for intraplaque microvascular leakage. Journal of the 
American College of Cardiology . 2009;53:1517 -1527  
31. Kockx MM, Cromheeke KM, Knaapen MW, Bos mans JM, De Meyer GR, Herman AG, Bult 
H. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in 
human atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology . 2003;23:440 -446  
32. Rhen T, Cidlowski JA. Antiinflammatory a ction of glucocorticoids --new mechanisms for old 
drugs. N Engl J Med . 2005;353:[ADDRESS_926243] . 2001;107:135 -142  
34. Gonz alez MV, Jimenez B, Berciano MT, Gonzalez -Sancho JM, Caelles C, Lafarga M, 
Munoz A. Glucocorticoids antagonize ap -1 by [CONTACT_683926]/phosphorylation of jnk 
without affecting its subcellular distribution. J Cell Biol . 2000;150:1199 -1208  
35. Bruun J M, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein -1 release 
is higher in visceral than subcutaneous human adipose tissue (at): Implication of 
macrophages resident in the at. J Clin Endocrinol Metab . 2005;90:2282 -2289  
36. Franchimont D, Ma rtens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, Belaiche J, 
Geenen V. Tumor necrosis factor alpha decreases, and interleukin -10 increases, the 
sensitivity of human monocytes to dexamethasone: Potential regulation of the glucocorticoid 
receptor. J Clin Endocrinol Metab . 1999;84:2834 -2839  
37. Poon M, Gertz SD, Fallon JT, Wiegman P, Berman JW, Sarembock IJ, Taubman MB. 
Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol 
fed rabbits. Atherosclerosis . 2001;155:371 -380  
38. Longenecker JP, Kilty LA, Johnson LK. Glucocorticoid influence on growth of vascular wall 
cells in culture. J Cell Physiol . 1982;113:197 -202  
39. Reil TD, Kashyap VS, Sarkar R, Freishlag J, Gelabert HA. Dexamethasone inhibits the 
phosphorylation of retinobl astoma protein in the suppression of human vascular smooth 
muscle cell proliferation. J Surg Res . 2000;92:108 -113  
40. Longenecker JP, Kilty LA, Johnson LK. Glucocorticoid inhibition of vascular smooth muscle 
cell proliferation: Influence of homologous extrace llular matrix and serum mitogens. J Cell 
Biol. 1984;98:[ADDRESS_926244] of 
dexamethasone on reactive oxygen species generation by [CONTACT_683927] -10 concentrations: A pharmaco dynamic study. Clin  Pharmacol Ther. 1999;66:58 -
65  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926245] C, Kuntz RE. The relative importance of arterial remodeling compared with 
intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal 
rabbit and the hypercholes terolemic yucatan micropig. Circulation. 1994;89:[ADDRESS_926246] C. Paradoxical arterial wall 
shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries. 
Circulation. 1995; 91:1444 -1449  
44. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell 
biology: Clues for the development of new preventive therapi[INVESTIGATOR_014]. Journal of the American 
College of Cardiology. 1991;17:758 -769  
45. Derksen WJ, de Vries JP, Vin k A, Velema E, Vos JA, de Kleijn D, Moll FL, Pasterkamp G. 
Histologic atherosclerotic plaque characteristics are associated with restenosis rates after 
endarterectomy of the common and superficial femoral arteries. Journal of vas cular surgery. 
2010;52:592 -599  
46. Patti G, Chello M, Pasceri V, Colonna D, Carminati P, Covino E, Di Germano S. 
Dexamethasone - eluting stents and plasma concentrations of adhesion molecules in 
patients with unstable coronary syndromes: Results of the historically controlled sesame 
study. Clin Ther. 2005;27:1411 -1419  
47. Patti G, Pasceri V, Carminati P, D'Ambrosio A, Carcagni A, Di Sciascio G. Effect of 
dexamethasone - eluting stents on systemic inflammatory response in patients with unstable 
angina pectoris or recent myocardial infarction undergoing percutaneous coronary 
intervention. Am J Cardio l. 2005;95:502 -505  
48. Han SH, Ahn TH, Kang WC, Oh KJ, Chung WJ, Shin MS, Koh KK, Choi IS, Shin EK. The 
favorable clinical and angiographic outcomes of a high -dose dexamethasone -eluting stent: 
Randomiz ed controlled prospective study. American heart journal. 2006;152:887 e881 -887  
49. Konig A, Leibig M, Rieber J, Schiele TM, Theisen K, Siebert U, Gothe RM, Klauss V. 
Randomized comparison of dexamethasone -eluting stents with bare metal stent 
implantation in p atients with acute coronary syndrome: Serial angiographic and sonographic 
analysis. American heart journal. 2007;153:[ADDRESS_926247] WF. Efficiency of drug 
delivery to the coronary arteries in s wine is dependent on the route of administration: 
Assessment of luminal, intimal, and adventitial coronary artery and venous delivery 
methods. J Vasc In terv Radiol. 2010;21:1555 -1564  
51. Penn MS, Ellis S, Gandhi S, Greenbaum A, Hodes Z, Mendelsohn FO, Strasse r D, Ting AE, 
Sherman W. Adventitial delivery of an allogeneic bone marrow -derived adherent stem cell in 
acute myocardial infarction: Phase i clinical stu dy. Circ Res. 2012;110:304 -311  
52. Sun J, Song Y, Chen H, Kerwin WS, Hippe DS, Dong L, Chen M, Zhou C, Ha tsukami TS, 
Yuan C. Adventitial perfusion and intraplaque hemorrhage: A dynamic contrast -enhanced 
mri study in the carotid artery. Stroke; a journal of cerebral circulation. 2013;44:1031 -1036  
53. Kerwin WS, Oikawa M, Yuan C, Jarvik GP, Hatsukami TS. Mr imagin g of adventitial vasa 
vasorum in carotid atherosclerosis. Magnetic resonance in medicine : official journal of the 
Society of Magnetic Resonance in Medicine / Society of Magnetic Resonanc e in Medicine. 
2008;59:507 -514  
54. Sigovan M, Hope MD, Dyverfeldt P, Saloner D. Comparison of four -dimensional flow 
parameters for quantification of flow eccentricity in the ascending aorta. J Magn Re son 
Imaging. 2011;34:1226 -1230  
55. Sigovan M, Rayz V, Gasper W, Alley HF, Owens CD, Saloner D. Vas cular remodeling  in 
autogenous arterio -venous fistulas by [CONTACT_683928]. Annals of biomedica l engineering. 
2013;41:657 -668  
56. Rayz VL, Boussel L, Ge L, Leach JR, Martin AJ, Lawton MT, McCulloch C, Saloner D. Flow 
reside nce time and regions of intraluminal thrombus deposition in intracranial a neurysms. 
Annals of biomedical engineering. 20 10;38:3058 -3069  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926248] 2019  Page 32 of 72 
 57. Li F, McDermott MM, Li D, Carroll TJ, Hippe DS, Kramer CM, Fan Z , Zhao X, Hatsukami TS, 
Chu B, Wang J, Yuan C. The association of lesion eccentricity with plaque morphology and  
components in the superficial femoral artery: A high -spatial -resolution, multi -contrast 
weighted cmr study. J Car diovasc Magn Reson. 2010;12:37  
58. Saam T, Ferguson MS, Yarnykh VL, Takaya N, Xu D, Polissar NL, Hatsukami TS, Yuan C. 
Quantitative evaluation of  carotid plaque composition by [CONTACT_683929]. Arteriosclerosis, 
thrombosis, and vas cular biology. 2005;25:[ADDRESS_926249] enhancement. J Magn Reson Imaging. 
2006;24:[ADDRESS_926250] fibrous cap and lipid -rich necrotic core 
size in atherosclerotic carotid plaque: Comparison of high -resolution, contrast -enhanced 
magnetic resonance imaging and histology. C irculation. 2005;112:3437 -3444  
61. Liu F, Xu D, Ferguson MS, Chu B, Saam T, Takaya N, Hatsukami TS, Yuan C, Kerwin WS. 
Automated in vivo segmentation of carotid plaque mri with morphology -enhanced probability 
maps. Magnetic resonance in medicine :  official journal of the Society of Magnetic 
Resonance in Medicine / Society of Magnetic Resonanc e in Medicine. 2006;55:[ADDRESS_926251] mri at 3t. J Magn Reson Imaging. 
2010;31:[ADDRESS_926252] D, Ortiz G, Small R, Davies 
JW, Kerwin WS, Hatsukami TS. In vivo accuracy of multispectral magnetic resonance 
imaging for identifying lipid - rich necrotic cores and intraplaque hemorrhage in advanced 
human carotid plaques. C irculation. 2001;104:2051 -2056  
64. Kerwin WSH, C. Chu, B. Xu, D. Hwang, J.N. Hatsukami, T. S. Yuan, C. Quantitative 
vascular analysis system for evaluation of atherosclerotic lesions by [CONTACT_683930]. Medical image 
computing and computer - assissted inte rvention - miccai 2001:786 -794  
65. Rayz VL, Boussel L, Acevedo -Bolton G, Martin AJ, Young WL, Lawton MT,  Higashida R, 
Saloner D. Numerical simulations of flow in cerebral aneurysms: Comparison of cfd results 
and in vivo mri measurements. J Biomech Eng. 2008;130:051011  
66. Rayz VL, Boussel L, Lawton MT, Acevedo -Bolton G, Ge L, Young WL, Higashida RT, 
Saloner D. Numerical modeling of the flow in intracranial aneurysms: Prediction of regions 
prone to thrombus formation. Ann  Biomed Eng. 2008;36:[ADDRESS_926253] mri: Analysis and correction of the 
effect of gradient field distortions. M agn Reson Med. 2003;50:[ADDRESS_926254], Siddiqui AH, Levy EI, 
Meng H. Hemodynamic -morpholo gic discriminants for intracranial aneurysm rupture. Stroke; 
a journal of cerebra l circulation. 2011;42:144 -152  
69. Macdonald RG, Panush RS, Pepi[INVESTIGATOR_85375]. Rationale for use of glucocorticoids in modification 
of restenosis after percutaneous transluminal coronary  angioplasty.  Am J Cardiol. 
1987;60:56B -60B  
70. Underhill HR, Yuan C, Yarnykh VL, Chu B, Oikawa M, Polissar NL, Schwartz SM, Jarvik GP, 
Hatsukami TS. Arterial remodeling in [corrected] subclinical carotid artery disease. JACC 
Cardiovasc Imaging. 2009;2:1381 -1389 ‚Ä® 
71. Dong L, Kerwin WS, Chen H, Chu B, Underhill HR, Neradilek MB, Hatsukami TS, Yuan C, 
Zhao XQ. Carotid artery atherosclerosis: Effect of intensive lipid therapy on the vasa 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926255] -enhanced mr imagin g. Radiology. 
2011;260:224 -231  
72. Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M,  
Brodmann M, Mustapha JA, Mena -Hurtado C, Jaff MR, Holden AH, Lyden SP. Stellarex 
Drug -Coated Balloon Treatment for Femoropopliteal Disease: 12 -Month outc omes from the 
Randomized ILLUMENATE Pi[INVESTIGATOR_683883]. Circulation AHA. 2017;  
117.028893  
73. Shroeder H, Werner M, Meyer D, Reimer P, Kruger K, Jaff M, Brodmann M. Low -Dose 
Paclitaxel -Coated Versus Uncoated Percutanoeus Transluminal Balloon A ngioplasty  for 
Femoropopliteal Artery Disease. Circulation AHA.  2017;135:2227 -2236.  
74. Katsanos K, Spi[INVESTIGATOR_41641] S, Kitrou P, Krokidis M, & Karnabatidis D. Risk of Death Following 
Application of Paclitaxel -Coated Balloons and Stents in the Femoropopliteal Ar tery of the 
Leg: A Systematic Review and Meta -Analysis  of Randomized Controlled Trials. J Am Heart 
Assoc . 2018;7(24):e011245 -e011245 ] 
75. FDA Letter from August 7th 2019 - https://www.fda.gov/medical -devices/letters -health -care-
providers/august -7-2019 -update -treatment -peripheral -arterial -disease -paclitaxel -coated -
balloons -and-paclitaxel) ] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926256] 2019  Page 34 of 72 
  
 
 
 
 
2 STUDY RATIONALE  
The fundamental hypothesis of this trial is that inhibition of inflammation at the site of 
injury will result in improved vascular healing and a sustained patent artery.  
This trial  is designed to explore the mechanism of restenosis by [CONTACT_683931] e 
approaches to drug delivery, intimal -based antiproliferative (paclitaxel) and adventitial -based 
anti-inflammatory  (Dexamethasone) . Safety concerns about paclitaxel have halted that 
treatment arm in favor of plain balloon angioplasty . Angioplasty creates a mechanical injury to 
the atherosclerotic vascular wall resulting in an inflammatory response as a multitude of growth 
factors and cytokines, catalysts for cellular proliferation and restenosis, are released. 
Subsequent restenosis is related to the magnit ude of the inflammatory response which  is more 
pronounced in the femoral artery than in other vascular beds. Clinical trials of therapi[INVESTIGATOR_683884], but were not fully developed in favor of 
anti-proliferati ve drugs, which have been highly successful in the coronary arteries, but not in 
leg arteries. Hence, the hypothesis that inhibition of vascular inflammation at the time of 
treatment can improve outcomes remains to be tested . Information on the healing res ponse of 
the vessel wall following treatment is limited. Duplex ultrasound and quantitative angiography 
are sensitive to changes in the vessel lumen but provide no information on the vessel wall or 
remodeling. Recent advances in magnetic resonance imaging (MRI) with black -blood and multi -
contrast imaging techniques now offer a non -invasive means to evaluate the geometric and 
compositional morphology of the vessel wall at sub -millimeter resolution. Further insights into 
the vascular wall can be obtained with  dynamic -contrast imaging techniques, which is capable 
of providing information on vessel wall perfusion arising from adventitial vasa vasorum. Thus, 
modern MRI affords deep structural and physiological insights into the vasculature and is ideally 
suited f or serial in vivo studies to monitor the biologic response to therapy.    
  
2.1 Risk / Benefit Assessment  
2.1.1  Anticipated Clinical Benefits  
In this trial, balloon angioplasty of the superficial femoral or popliteal artery will be followed with 
either:  
1. an adventitial infusion of dexamethasone sodium phosphate (USB, 4mg/mL)  
or  
2. no further treatment . 
There are no guaranteed benefits for subjects participating in the trial.   
2.1.2  Anticipated Adverse Events  to balloon angioplasty of the SFA  
‚Ä¢ Additional intervention  
‚Ä¢ Allergic reaction to drugs or contrast  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926257] 2019  Page 35 of 72 
 ‚Ä¢ Aneurysm or pseudoaneurysm  
‚Ä¢ Arrhythmias  
‚Ä¢ Embolization  
‚Ä¢ Hematoma  
‚Ä¢ Hemorrhage including at the puncture site  
‚Ä¢ Hypotension/hypertension  
‚Ä¢ Inflammation  
‚Ä¢ Occlusion  
‚Ä¢ Pain or tenderness  
‚Ä¢ Pneumothorax or hemothorax  
‚Ä¢ Sepsis/infection  
‚Ä¢ Shock  
‚Ä¢ Stroke  
‚Ä¢ Thrombosis  
‚Ä¢ Vessel dissection, perforation, or rupture  
2.1.3  Possible Risks of Participation in this Clinical Trial  
[IP_ADDRESS]  Procedural Risks of Adventitial Infusion  
Likely: (likelihood >5%)  
‚Ä¢ Irritation or extravasation of blood at the perivas cular injection site ‚Äì typi[INVESTIGATOR_683885]-limited. Less damage than balloon angioplasty or atherectomy.  
‚Ä¢ Perivascular air injection ‚Äì due to incorrect preparation of catheter for injection; 
harmless, involves a volume of <1.5mL and is typi[INVESTIGATOR_115216] -limited (air is reabsorbed).  
‚Ä¢ Device balloon rupture ‚Äì due to incorrect preparation of the device balloon; low 
frequency event in prior device use and testing as there is a pressure relief valve to 
prevent over -inflation of the device balloon; there are no ad verse effects due to simple 
balloon rupture (device is discarded after removal from the patient).  
Rare: (likelihood <1%)  
‚Ä¢ Vessel spasm ‚Äì due to incorrect catheter sizing for target vessel; usually self -limited, but 
may require further treatment (balloon ang ioplasty) if severe.  
‚Ä¢ Vessel dissection ‚Äì due to incorrect catheter sizing for target vessel, excessive vessel 
wall thickness or mis -administration of medication; may require further treatment 
(balloon angioplasty or stent) if severe.  
‚Ä¢ Vessel thrombosis ‚Äì due to incorrect catheter sizing for target vessel or prolonged 
inflation of catheter balloon; may require further treatment (balloon angioplasty, stent, 
embolectomy, thrombolysis) if severe.  
‚Ä¢ Distal emboli ‚Äì due to incorrect catheter sizing for target vessel  or disruption of vessel 
wall plaque; may require further treatment (embolectomy, thrombolysis) if severe.  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926258] 2019  Page 36 of 72 
 Extremely Rare: (likelihood <0.1%)  
‚Ä¢ Arteriovenous fistula ‚Äì complication of perivascular injection; extremely rare given 
needle length and diameter; m ay require further treatment (stent) if severe.  
‚Ä¢ Pseudoaneurysm ‚Äì bleeding complication at site of perivascular injection, extremely rare 
given needle length and diameter; may require further treatment if severe.  
‚Ä¢ Device balloon fragmentation with emboli ‚Äì device failure, extremely rare event in prior 
device use and testing as there is a pressure relief valve to prevent over -inflation of the 
device balloon; may require further treatment (embolectomy, thrombolysis) if severe.  
‚Ä¢ Device component separation - due to incorrect use of the device or manufacturing 
failure; rare event in prior device use testing as there is a pressure relief valve to prevent 
over-inflation of the device balloon; may require further treatment (embolectomy) if 
components embolize.  
[IP_ADDRESS]  Risks o f Dexamethasone  
The Contraindications, Warnings, Precautions, Adverse Reactions and Overdosage sections of 
the Dexamethasone Sodium Phosphate Injection, USP, package insert should be consulted 
prior to administration of the drug.  
We plan to administer a single dose of dexamethasone in the perivascular space. Therefore, we 
expect the risk of systemic adverse effects typi[INVESTIGATOR_683886], long -term, supra -
physiologic doses of dexamethasone will be very low. This expectation is bas ed on the following 
data:  
1. Delivery of dexamethasone  (DEX)  will be localized to the perivascular tissues . Thus we 
expect the pharmacokinetics to be similar to the local administration of dexamethasone 
in soft tissue. A study comparing adventitial drug delivery  of DEX  vs. a drug -infusion 
balloon vs. intravenous administration  of DEX  in swine coronary arteries found  that 
adventitial delivery was the only method with a high -concentration of study drug in the 
target tissue (myocardium) and negligible levels in liver, lungs, blood or urine [ 50]. 
2. Each infusion of dexamethasone in the range of 2 to 7.5 mL (1.6 mg dexameth asone per 
1 cm of target artery, with a total dose of 6.4 to 24 m g for expected treat ed segment  
lengths  of approximately 4 -15 cm) is within the common dose range of dexamethasone 
for adults per the manufacturer‚Äôs dosing instructions.  
Likely: (likelihood >5 %) 
‚Ä¢ None  
Less Likely: (likelihood <5%)  
‚Ä¢ Hyperglycemia, particularly in patients with diabetes - effect is likely transient 
(<24hrs), possible need for increased insulin or oral hypoglycemic agents.  
Rare: (likelihood <1%)  
‚Ä¢ Hypertension - likely transient, poss ible need for increased antihypertensive therapy.  
Extremely Rare: (likelihood <0.1%)  
‚Ä¢ Allergic reaction - typi[INVESTIGATOR_683887]. Can range 
from allergic dermatitis to severe, life -threatening anaphylactic reactions support ive 
care and monitoring. Dexamethasone will be administered in the OR with the patient 
under observation by [CONTACT_683932].  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926259] 2019  Page 37 of 72 
 ‚Ä¢ Vessel wall necrosis - multiple studies with dexamethasone eluting stents in lab 
animals and humans have not found evidence of vessel wall necrosis (see 
background studies) but this is a theoretical risk that would require further 
intervention (stenting) to treat.  
‚Ä¢ Fluid and electrolyte disturbances: sodium retention, fluid retention, congestive heart 
failure in s usceptible patients, potassium loss, hypokalemic alkalosis, or 
hypertension.  
‚Ä¢ Musculoskeletal: muscle weakness, steroid myopathy, loss of muscle mass, 
osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and 
humeral heads, pathologic f racture of long bones, or tendon rupture.  
‚Ä¢ Gastrointestinal: peptic ulcer with possible subsequent perforation and hemorrhage, 
perforation of the small and large bowel, particularly in patients with inflammatory 
bowel disease, pancreatitis, abdominal disten tion, or ulcerative esophagitis.  
‚Ä¢ Dermatologic: impaired wound healing, thin fragile skin, petechiae and ecchymosis , 
erythema, increased sweating, may suppress reactions to skin tests, burning or 
tingling, especially in the perineal area (after I.V. injecti on), or other cutaneous 
reactions, such as allergic dermatitis, urticaria, angioneurotic edema.  
‚Ä¢ Neurologic: convulsions, increased intracranial pressure with papi[INVESTIGATOR_044] 
(pseudotumor cerebri) usually after treatment, vertigo, headache, or psychic 
disturban ces. 
‚Ä¢ Endocrine: menstrual irregularities, development of cushingoid state, suppression of 
growth in children, secondary adrenocortical and pi[INVESTIGATOR_80567], 
particularly in times of stress, as in trauma, surgery, or illness, decreased 
carbohydrat e tolerance, manifestations of latent diabetes mellitus, increased 
requirements for insulin or oral hypoglycemic agents in diabetics, or hirsutism.  
‚Ä¢ Ophthalmic: posterior subcapsular cataracts, increased intraocular pressure, 
glaucoma, or exophthalmos.  
‚Ä¢ Meta bolic: negative nitrogen balance due to protein catabolism.  
‚Ä¢ Cardiovascular, myocardial rupture following recent myocardial infarction (see 
WARNINGS in drug labeling).  
‚Ä¢ Other: anaphylactoid or hypersensitivity reactions, thromboembolism, weight gain, 
increas ed appetite, nausea, malaise, or hiccups.  
‚Ä¢ The following additional adverse reactions are related to parenteral corticosteroid 
therapy: rare instances of blindness associated with intralesional therapy around the 
face and head, hyperpi[INVESTIGATOR_683888], subcutaneous and 
cutaneous atrophy, sterile abscess, infection, postinjection flare (following intra -
articular use), or charcot -like arthropathy  
[IP_ADDRESS]  Risks of Paclitaxel  
Paclitaxel is the active agent on FDA approved DCBs.  Paclitaxel inhibits smooth muscle cell 
(SMC) and fibroblast proliferation, migration, and matrix synthesis by [CONTACT_683933] (stabilizes). Because SMC s and fibroblast s are the pri mary cellular components 
of the neointimal hyperplastic response, they are thought to be the mechanism by [CONTACT_683934].  Other agents that are known as excipi[INVESTIGATOR_683889].  INPACT Admiral DCB uses 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926260] candy, diabetic sweeteners (sorbitol), and shampoo, 
lubricants, cosmetics (polysorbate).   Similarly, polyethylene  glycol  is used  in household products 
like creams, lubricants, toothpaste, gum and has several industrial and biologic uses as well. 
The combination of [paclitaxel + urea ], [paclitaxel + sorbitol and polysorbate ] and [crystalline 
paclitaxel + polyethylene glycol] are known as the matrix on the balloon surface.   
The pharmacokinetics of paclitaxel release following treatment with a balloon catheter has been 
studied.  The time to maximal plasma concentration following DCB inflation is a bout 10 minutes 
and the Cmax is less than 8 ng/ml in each balloon. Typi[INVESTIGATOR_683890] 135 ‚Äì 175 mg/m2, yielding a C max that is 2170 -3650 ng/ml. Hence maximal 
plasm a levels of paclitaxel are over 200 -fold less than typi [INVESTIGATOR_683891]. 
Plasma levels fall to less than 3 ng/ml within one hour‚Äôs time. The pharmacokinetics of paclitaxel 
demonstrated a bi -exponential decay characterized by a rapid redistribution and then and log -
linear elimination phase. The h alf-life is [ADDRESS_926261] been performed but drugs 
metabolized by [CONTACT_63931] e nzymes may interfere with paclitaxel metabolism.  
Concerns about the safety of paclitaxel  (PTX) coated devices have led to recommendations  by 
[CONTACT_683935] ‚Äúfor many patients, alternative treatment options for paclitaxel -coated balloons and 
paclitaxel -elutin g stents provide a more favorable benefit -risk profile.‚Äù Subjects are no longer 
treated with paclitaxel DCBs. In this study, those subjects already treated with PTX will be 
monitored for adverse events.  
Potential adverse events  
Likely: (likelihood >5%)  
‚Ä¢ None  
Less Likely: (likelihood <5%)  
‚Ä¢ increased risk of death  
Rare: (likelihood <1%)  
‚Ä¢ none  
Extremely Rare: (likelihood <0.1%)  
‚Ä¢ Hypersensitivity reaction to paclitaxel manifested as a cutaneous rash  
‚Ä¢ Emboli of the matrix INPACT balloon  
‚Ä¢ Peripheral neuropathy  
 
[IP_ADDRESS]  Risk s of MRI and Gadolidium Contrast Agent  
Gadolinium reactions may occur but they are extremely rare. The incidence of adverse 
reactions ranges from  1-1.4% and may consist of nausea and vomiting to anaphylaxis. Life -
threatening reactions to gadolinium are  extremely rare. Mild reactions are also rare and usually 
self-limited. In patients who have compromised kidney  function, the use of gadolinium agents 
has also been associated with a rare but serious condition, called  Nephrogenic Systemic 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926262] 2019  Page 39 of 72 
 Fibrosis (NSF). Kidne y function is measured by a value termed eGFR (estimated  Glomerular 
Filtration Rate) in units of ml/min/1.73m2. There have been no reported cases of NSF in 
individuals  with eG FR > 60 ml/min/1.73m2. Following the guidelines of the MR Safety 
Committee at UCS F/SFVAMC and  UW, we will measure creatinine levels and determine the 
eGFR in all patients in this study as part of their preoperative  assessment. If eGFR is < 30 
ml/min/1.73m2 then subjects are excluded from participation in this  research study. If eGFR is < 
60 ml/min/1.73m2 but > 30 ml/min/1.73m2 the minimal dose of gadolinium necessary will be 
used after consultation with a radiologist.  
The FDA is investigating the risk of br ain deposits following the repeated use of gadolinium 
based contrast agents (GBCAs) for MRI. Recent publications in the medical literature have 
reported that deposits of GBCAs remain in the brains of some patients  who undergo four or 
more contrast MRI scan s, long after the last administration.  It is unknown whether these 
gadolinium deposits are harmful or can lead to adverse health effects. These effects have only 
been seen in the linear chelates of Gd.  For this reasons, the protocol will avoid the use of  linear 
chelates.   
The additional risk of magnetic resonance imaging (MRI) requires that the subject be placed in a 
small and confined space for periods of time, and this can lead to claustrophobia in some 
patients. Electric implants, such as cardiac pace makers, may be susceptible to interference 
from the magnet and RF fields produced by [CONTACT_683936]. Persons with cardiac 
pacemakers or other implanted electronic devices are prohibited from entering a zone where the 
magnetic field exceeds five gauss. T he magnetic field of the MR instrument is strong enough to 
forcefully attract ferromagnetic objects. The inadvertent introduction of ferromagnetic materials 
in the proximity to the magnet may result in such objects becoming projectiles, which could 
present  a risk to subjects and other persons. This force can cause a ferromagnetic implant, 
such as an aneurysm clip, surgical clip, or prosthesis, to move or be dislodged. Entry to the 
magnet area is possible only through a single door beside the operator‚Äôs cons ole, which is 
guarded by [CONTACT_683937]. A technologist screens all persons before they 
enter  the magnet area. In addition, warning signs are posted.  
The Bureau of Radiologic Health has issued guidelines for the amount of radiofrequency energy 
which may be  employed in imaging subjects in order to ensure that the procedure does not 
entail more than minimal risk. If  energy beyond this value is used, some subjects may undergo 
an evaluation in body temperature. If energy  which grossly exceeds  this guideline is used, the 
subject may receive soft tissue burns. Both the Siemens and  the GE MR System includes both 
software and hardware limits, which prevent selection of imaging sequences  from exceeding the 
energy deposition guidelines of the Bureau  of Radiologic Health. All studies will be  conducted 
below this energy limit.  
[IP_ADDRESS]  Other Risks  
The following study activities involve only minimal risk to participants:  
‚Ä¢ Blood Draw  - Phlebotomy involved in this study poses minimal risk to the subject; 
however, b ruising may be expected around the venipuncture site. Occasional, 
dizziness and vasovagal epi[INVESTIGATOR_254809].  
‚Ä¢ Ankle Brachial Index (ABI)  - May involve minor discomfort similar to a standard 
brachial blood pressure measurement.  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926263] 2019  Page 40 of 72 
 3 STUDY OBJECTIVES  
3.1 Primary Objective  
The primary objective is to assess the mechanisms of vascular healing following balloon 
angioplasty treatment to stenotic arteries from atherosclerosis.  Vascular healing will be 
assessed by [CONTACT_683938] (PWV) from [ADDRESS_926264] -
angioplasty to 12 months  
3.2 Secondary Objectives  
Secondary objective s include:  
1. To determine whether DEX infusion will result in less inflammation as measured by 
[CONTACT_41225] (MCP -1, CRP, and IL -1Œ≤) and tissue imaging ( Ktrans) markers of inflammation  
2. To determine whether patient -specific physiological factors correlate with vascular 
healing  
 
  
4 STUDY DESIGN  
4.1 Study Overview  
This is a prospective, multicenter, randomized trial to determine the mechanisms of vascular 
healing . The study will evaluate subjects with peripheral artery disease (PAD) who require an 
endovascular intervention of the femoropopliteal arterial segment (SFA/Popliteal)  to restore 
blood flow to the leg.  
The total duration of su bject participation will be 36 months. Total duration of the study is 
expected to be five years . 
4.2 Specific Aims  
1. To determine whether adventitial DEX infusion will result in improved vascular 
healing following femoral artery angioplasty , with the following Statistical 
Hypotheses : 
a. Advent itial DEX infusion will result in reduced change in percent wall volume 
(ŒîPWV) within the treated segment.  
b. Adventitial DEX infusion will result in improved vascular remodeling of the treated 
segment.  
2. To determine whether DEX infusion will result in less in flammation as measured by 
[CONTACT_41225] (MCP -1, CRP, and IL -1Œ≤) and imaging ( Ktrans) markers of inflammation, with the 
following Statistical Hypotheses : 
a. Adventitial DEX infusion will result in reduced peri -operative inflammatory profile.  
b. Adventitial DEX infusion will result in less adventitial perfusion (a surrogate of 
inflammation) as measured by [CONTACT_683939] -enhanced 
MRI.  
c. Peri-operative inflammatory profile will be associated with ŒîPWV.  
3. To determine whether patient -specific physi ological factors correlate with 
vascular healing , with the following Statistical Hypotheses : 
a. Treat ed segment remodeling will be associated with the fibrous volume in 
plaques.  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926265]- intervention MRI scan to 12 months between DEX  treated and non-DEX (PTX or POBA)  
treated patients.  
The treated segment is defined as the length of vessel , encompassing the index lesion , that has 
undergone successful revascularization, from normal back to normal artery.  
5.2 Secondary Endpoints  
Secondary endpoints include:  
1. Change in wall volume (WV) without a change in total vessel volume (TVV) at 12 months  
2. Change in perioperative inflammatory  profile (MCP -1, CRP, IL -1ÔÅ¢) at 12 month s 
3. Change in Ktrans from 1 month  to 6 months  
4. Change in lumen volume (LV) relative to total vessel volume (TVV) at [ADDRESS_926266] study  status based on subjects receiving reintervention on < 75% or 
ÔÇ≥ 75% of treated segment.  
5.3 Safety Endpoints  
The i ncidence of adverse events  will be the primary metric for the evaluation of safety.   A Data 
Safety Monitoring Committee will meet on a regular, semi -annual basis to review the trial and 
address all safety issues (See Sec . 15 Data Safety Monitoring ) 
5.[ADDRESS_926267] Status & Study Completion : 
For subject to complete their participation in this study they must:   
1. Undergo follow -up for 36-month period after index procedure, completing all 
assessments in the Schedule of Assessments.  
 
2.  Subject develops restenosis after the  1-month study follow -up, requiring 
reintervention of ÔÇ≥ 75% of treated segment.  
If subject does not complete the study following the above indications, please see section 13.1 
for specifics on Early Discontinuation/Withdrawals.  
If subject develops restenosis after the  1-month study follow -up, requiring reintervention of 
<75%  of the treated segment, please see section 11. 10 for specifics on recording Unplanned 
Visits for Index Leg Reintervention and continuing  follow -up. 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926268] SELECTION  
6.1 Study Population  
Subjects with a diagnosis of peripheral artery disease who require an endovascular intervention 
of the femoropopliteal arterial segment (SFA/Popliteal)  to restore blood flow to the leg may be 
eligible for the study.  Screening criteria will be used to ident ify sub jects eligible for enrollment. 
Final eligibility and r andomization will occur intra -operativ ely following adjudication of Procedural 
Inclusion/E xclusion criteria.   
6.2 Inclusion Criteria  
Screening  Inclusion Criteria : 
1. Male or non -pregnant female ‚â• [ADDRESS_926269] Clinical Category 2 -6 
4. Stenosis detected by [CONTACT_683907] ‚Äôs opi[INVESTIGATOR_683892]  
5. Patient is willing to provide informed consent and comply with the required fo llow up 
visits, testing s chedule, and medication regimen  
6. eGFR ‚â• 30 or threshold established by [CONTACT_683940] : 
1. De novo atherosclerotic lesion qualifying for angioplasty  
2. A patent artery proximal to  the index lesion.  Concomitant inflow procedures , 
including open femoral artery endarterectomy or stenting of the iliac arteries , are 
permissible.  
3. >50% diameter stenosis of the superficial femoral artery and/or popliteal artery 
(between the pr ofunda and tibioperoneal trunk)  
4. Reference vessel diameter ‚â•3 mm and ‚â§ 8mm  
5. Successful wire crossing of lesion   
6. Successful angioplasty of the index lesion  or part of the index lesion , defined as 
‚â§30% residual lumen stenosis compared with adjacent non-diseased lumen 
diameter, without flow -limiting dissection  
6.3 Exclusion Criteria  
Screening Exclusion Criteria : 
1. Any contraindication to receiving an MRI  
2. Pregnant, nursing, or planning on becoming pregnant in < 2yrs  
3. Life expectancy of < 1 yr 
4. History of solid organ transplantation  
5. Patient actively participating in another investigational device or drug study  
6. History of hemorrhagic stroke within 3 months  of index procedure  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926270] 2019  Page 43 of 72 
 7. Previous or planned surgical or interventional procedure within 30 days of index 
procedure  
8. Chronic renal insufficiency of eGFR < [ADDRESS_926271] me dia, gadolinium,  aspi[INVESTIGATOR_683893]  
12. Systemic fungal infection  
13. Acute limb ischemia  
14. Prior participation of the index limb in the current study (contralateral treatment is 
allowed)  
15. Patient is being treated with long -term steroids ( not including  treatment of a bronchial 
condition with inhaled steroids ) 
 
Procedural Exclusion Criteria : 
1. Index l esions extending into the  tibial trifurcation or above the profunda . Note : the 
outflow tibial artery can be treated concomitantly. Similarly , the common femoral 
artery can be treated concomitantly , either with open endarterectomy and  patch 
angioplasty or  with endovascular methods.  However , the index lesion can not be 
contiguous with either the CFA or the tibial trifurcation.  
2. Circumferential calcification at index lesion, which in the judgment of the investigator 
would prevent penetration of the M icro-Infusion catheter needle through the vessel 
wall 
3. Inadequate distal outflow defined as no patent tibial arteries  (>50% st enosis) . The 
outflow vessel can be established at the time of primary treatment  
4. Use of adjunctive therapi[INVESTIGATOR_683894]. Chocolate balloons and/or 
scoring balloon s are allowed, if used below reference diameter.  
[ADDRESS_926272] therapi[INVESTIGATOR_683895]-existing or emergent conditions are  allowed  except for treatments 
noted in the ex clusion criteria described above .   
 
8 STUDY TREATMENTS  
8.1 Method of Assigning Subjects to Treatment Groups  
Upon confirming eligibility, and after consultation with treating physicians, patients will be 
assigned to a treatm ent group (DEX infusion or POBA ) using a block randomization scheme.  A 
unique set of blocks will be created for each site.   
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926273] 
medium  (320 mg I/ml) .  A copy of the dexamethasone sodium phosphate USP label is included 
as Appendix 4 . The trial also uses a M icro-Infusion cathe ter, used in accordance with the IFU.  
8.2.1  Packaging and Labeling  
 DEX is widely available throughout the hospi[INVESTIGATOR_683896].  It is 
available in all anesthesia carts and is commonly used intravenously to treat allergic reactions 
during surgery.  
8.3 Supply of DEX at the Site  
Each site is responsi ble for obtaining DEX and maintaining inventory.  
8.3.1  Dosage/Dosage Regimen  
This protocol will utilize a 4 mg/ml preparation of Dexamethasone Sodium Phosphate Injection,  
USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate  
equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The  
Dexamethasone Sodium Phosphate Injection, USP will be mixed 80%:20% with iodinated  
contrast medium  (iodixanol, 320 mg I/mL ) to diagnose the distribution of injectate. This will 
result in a final concentration  of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone 
sodium phosphate, or 2.67 mg  dexamethasone) and 60 -74 mg iodine in each mL  of solution.  
The dosage proposed for this clinical trial is 1.6 mg of Dexamethasone Sodium Phosp hate per 
cm of lesion. The  typi[INVESTIGATOR_683897] 4 -15 cm in length  so each infusion will 
range  from 2 to 7.5 ml for a total one -time perivascular dosage in each patient of 6.4 to 24 m g.  
Multiple infusions are possible and thus allowance of up to 20% loss due to variability in 
anatomy, distribution patter n, or intravascular diagnostics . The 4 mg/ml dexamethasone solution 
will be diluted to 3.2 mg/ml with contrast medium to track infusions.  Based  on the distribution 
seen with similar infusions, each 0.[ADDRESS_926274] operating procedures 
per institutional policy.  
8.3.4  Storage  
 DEX will be stored in accordance with the manufacturer‚Äôs label or IFU.  The expi[INVESTIGATOR_683898] a ny expi[INVESTIGATOR_683899].     
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926275] will be 
maintained by [CONTACT_464] .   
8.5 Supply of Devices at the Site  
The intent  of this trial is to study the mechanisms of angioplasty failure.  Therefore,  there are no 
investigational devices used in the trial.  All devices and drugs used in the study are FDA 
approved and are being used as indicated.  The site is responsible for bu ying angioplasty 
balloons and equipment including adventitial infusion catheters.  
9 STUDY PROCEDURES AND GUIDELINES  
A Schedule of Events representing the required testing procedures to be performed for the 
duration of the s tudy is diagrammed in Section 10 ‚ÄúSchedule of Assessments‚Äù . 
Prior to conducting any study -related activities, written informed consent and the Health 
Insurance Portability and Accountability Act (HIPAA) authorization must be signed and dated by 
[CONTACT_423] . If appropriate, assent must also be obtained prior to conducting any study -related 
activities.   
 
9.[ADDRESS_926276].  
Postmenopausal is further defined:  
1. If the woman is over 50 years of age and has experienced no menstruation for 12 
consecutive months, she is ‚Äúpos tmenopausal‚Äù.  
2. If the woman is under [ADDRESS_926277], 
then she is ‚Äúpostmenopausal‚Äù.  
Assessment will occur at: Screening.  
9.1.2  Demographics   
Demographic information (date of birth, gender, race) will be recorded . 
Assessment will occur at: Baseline.  
9.1.3  Medical History  
Relevant medical history, including history of current disease, other pertinent cardiovascular 
history, and information regarding underlying diseases will be recorded.  
Assessment will occur at: Baseline.  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926278] 2019  Page 46 of 72 
 9.1.4  Concomitant Medications  
All concomitant medication and concurrent therapi[INVESTIGATOR_683900].  Dos age, units , route, frequency of 
administration, and dates of medication will be captured.  
Assessment s will occur at: Baseline, Post-Op, Month 1, Month 6, and Month 12.  
9.1.[ADDRESS_926279] clinical care. Results from these exams will be recorded by [CONTACT_464].  
Assessment s will occur at: Baseline, Post-Op, Month 1, Month 6, and Month 12.  
9.1.6  Physical Examination  
An appropriate physical examination will be performed by [CONTACT_42483] (MD, NP, PA , 
RN or trained research assistant ) as part of their standard clinical care . Results from these 
exams will be recorded by [CONTACT_464].  
Assessment s will occur at: Baseline, Post-Op, Month  1, Month 6, and Month 12. 
9.1.7  Vascular Examination  
A comp lete vascular pulse examination, Ankle -Brachial Index (ABI), and Rutherford 
Categorization will be performed by [CONTACT_42483] (MD, NP, RN, or PA) or research staff  
under the supervisi on of a study investigator . Results of the exam will be recorded by [CONTACT_38992].  
The Ankle -Brachial Index (ABI) examination will be performed according to current, accepted 
guidelines.  Subjects will rest 10 minutes in a supi[INVESTIGATOR_683901]. The ABI will be 
defined as the ratio between the higher of the two pedal systolic blood pressures (dorsalis pedis 
and posterior tibialis) and the higher of the two systolic brachial pressures. A continuous wave 
Doppler, between 5 and 12 MHz, will be used to measure the systolic pressures in both the 
dorsalis pedis and posterior tibial arteries in each leg, as well as the brachial arteries in each 
arm. The ABI will be calculated for both legs. In the event the pedal / tibial vessels are 
noncompressible , a toe brachial index may be used.  
Rutherford Categories will be defined by [CONTACT_4676] -reported pai n-free walking distance. Table [ADDRESS_926280] Categories to objective criteria and to common patient -reported distances.  
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926281] Categorie s  
Category  Clinical description  Objective criteria  
0 Asymptomatic ‚Äîno 
hemodynamically significant 
occlusive disease  Normal treadmill or reactive hyperemia test  
1 Mild claudication  Completes treadmill exercise‚Ä†; AP after 
exercise >[ADDRESS_926282] treadmill 
exercise‚Ä† and AP after exercise <[ADDRESS_926283] pain  Resting AP <40 mm Hg, flat or barely 
pulsatile ankle or metatarsal PVR; TP <30 
mm Hg  
5 Minor tissue loss ‚Äî
nonhealing ulcer, focal 
gangrene with diffuse pedal 
ischemia  Resting AP <60 mm Hg,  ankle or 
metatarsal PVR flat or barely pulsatile; TP 
<40 mm Hg  
6 Major tissue  loss‚Äîextending 
above TM level,  functional 
foot no longer salvageable  Same as category 5  
*Grades II and II, categories 4, 5, and 6 are embraced by [CONTACT_442025].  
‚Ä†Five minutes at 2 mph on a 12% incline.  
 
Assessment s will occur at: Baseline, Post-Op, Month  1, Month 6, and Month 12 . 
 
Telephone assessment of changes in medical history ( medications, cardiovascular events , 
hospi[INVESTIGATOR_602] , etc. ) will occur at 24 and 36 months.  
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926284] 2019  Page 48 of 72 
 9.2 Laboratory Measurements  
9.2.1  Research Laboratory Measurements  
Research laboratory assessments include : 
1. Serum C -Reactive Protein (CRP)  
2. Monocyte Chemotactic Protein 1 (MCP -1) 
3. Interleukin -1 Beta (IL -1Œ≤).   
A complete description of the c ollection requirements are outlined in Appendix 2.  Briefly, a 20 ml 
sample  will be obtained (1x [ADDRESS_926285] tubes ). The samples will be 
centrifuged, aliquoted, and stored at -80¬∞C.  
Assessment will occur at: Baseline, Post-Operative Day #1, Month [ADDRESS_926286]‚Äôs chart 
by [CONTACT_464].  
Assessment of clinical labs for baseline will occur within 30 days prior to the index procedure  
(Day 0)  
Analyses recorded at baseline include:  
1. Serum chemistry  
2. Complete blood count (hemoglobin, hematocrit, white blood cell count, white 
blood cell differential, and platelet count)  
3. Lipid panel  
4. Coagulation studies.  
Following a successful index p rocedure at Day 0, only eGFR will be collected  for clinical labs .  
Assessments of eGFR will occur at: POD Day #1, Month 1, Month 6 , and Month 12 . 
9.3 Adverse Events  
Information regarding occurrence of adverse events will be captured throughout the study. 
Duration (start and stop dates), severity/grade, outcome, treatment and relation to the index 
procedure  will be recorded on the case report form (CRF).  
9.[ADDRESS_926287].    
Please refer to Appendix 8. Walking Impairment Questionnaire for more details  
Assessment s will occur at: Baseline, Month 1, Month 6, and Month 12.  
  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926288] 2019  Page 49 of 72 
  
9.5 Treated Segment Registration  
During the index procedure, the investigator will identify an ‚Äúindex lesion ‚Äù, which is a segment of 
the SFA and/or popliteal artery  that meets the procedural inclusion/exclusion criteria (see 
Section 6). The index lesion will fall  within the following constraints:  
1. The index lesion will be between  the femoral  bifurcation and the infrapopliteal trifurcation  
(specifically, the take-off of the anterior tibial artery) .  
2. If the femoropopliteal arterial segment has diffuse disease , there  must be at least 2 cm 
of ‚Äúnormal‚Äù vessel proximal and distal to the index lesion . A ‚Äúnormal ‚Äù vessel is defined as  
having  < 20% stenosis.  
3. If a subject has multiple lesions that meet the procedural inclusion/exclusion criteria , the 
investigator may choose any qualif ied lesion as the index lesion .  
A Glow ‚ÄòN Tell radiopaque tape (LaMa itre Vascular, Burlingame MA) will be placed at the 
subject‚Äôs medial tibial spi[INVESTIGATOR_683902] ‚Äú0 cm‚Äù mark, topographically overly ing the knee cap and the 
numbers increase proximally . The lesion length, location, and degree of stenosis/occlusion will 
be documented.  
Following a  successful revascularization , the treated segment will be registered to the nearest 
millimeter on the tape , including [ADDRESS_926289] the Randomization ID on procedural CRFs, open the envelope, and reveal the 
assignment (DEX vs POBA ).    
A full description of the Randomization process is given in Sec. 16.4  ‚ÄúSample Size & 
Randomization ‚Äù. 
9.7 DEX Infusion  
Patients randomized to the DEX group will receive dexamethasone infusion after the primary 
revascularization procedure and before any provisio nal stenting. The equipment, order of 
operations, and dosing instructions are described below.  
9.7.1  Equipment  
A micro -infusion catheter (Mercator Cricket, Bullfrog, or Bullfrog XL) will be used to deliver FDA -
approved Dexamethasone Sodium Phosphate Injection, U SP, 4 mg/ml, mixed with FDA -
approved non -ionic contrast medium to the index lesion  
9.8 Order of Operations  
Research procedures will be performed in between steps of a clinical procedure. In general, the 
order of operations is as follows:  
1. Establish vascular acc ess 
2. Initial angiogram  
3. Place Glow ‚ÄòN Tell tape 
4. Index lesion registration  with respect to knee joint  
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926290] 2019  Page 50 of 72 
 5. Primary revascularization  
6. Assessment of Procedural Inclusion /Exclusion  Criteria  
7. Treated segment registration with respect to knee joint  
8. Randomization  
9. DEX infusion or POBA  
10. Provisional stenting  
11. Completion angiography  
 
Primary Revascularization : A balloon shall be selected such that the  diameter  is 1 mm less 
than the vessel reference diameter. To secure good results, slow inflation, prolonged  inflation  (3 
min) at nominal pressure should be used. O ne additional inflation  may be used to ensure good 
results.  If there is > 30 % residual stenosis, th at portion of the stenosis is ineligible to be included 
and a stent will be placed.  However,  if there  is a portion of the lesion that has adequate results 
and there is no anticipation of a stent , then the successfully PTA treated , but non -stented , 
segment can be registered as the treated segment . 
  
For subjects randomized to POBA , If the patient is randomized to POBA , then an appropriate 
sized device  may be used according to the IFU , at a 1:1 artery :balloon size ratio. The 
Investigator will complete the clinical portions of the procedure (e.g. completion angiograms)  per 
standard of care, Provisional stenting of the treated segment is allowed if clinically indicated.  
For subjects randomized to DEX , the Investigator will infuse dexamethasone (1.6 mg / cm 
lesion length). The investigator may administer DEX at multiple sites  along the treated segment  
and may reposition the Micro -Infusion Catheter as needed to establish successful distribution of 
the d rug along the treated segment . 
Imaging will be saved for the Core Lab (UCSF VipeRx Lab)  to assess the technical  success of 
drug administration, the extent of circumferential (or lateral using 2 -dimensional X -ray 
fluoroscopic guidance) and longitudinal cove rage of the artery by [CONTACT_683941]. The following 
scale will be used to grade the pattern of distribution:  
Technical success is defined as grades A, B or C   
 
Table 2: Diffusion grades and distribution patterns  
 
Provisional stenting of the treated segment is allowed if clinically indicated.  
 

CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926291] 2019  Page 51 of 72 
 9.9 Research MRI  
A research MRI will be performed to assess change in Percent Wall Volume (Œî PWV ) and 
transfer constant ( Ktrans) following the procedure. Specific details of the pr otocol are discussed 
below.  
Assessment s of ŒîPWV will occur: at Post-Op, Month 6, and Month 12.   
Assessment s of Ktrans will occur at: Month 1 and Month 6 . 
9.9.1  Equipment  
A research MRI wi ll be obtained on either a 3T S iemens Skyra  MRI (Erlangen [LOCATION_013]) 
(SFVAMC/UCSF) or a 3T Philips Achieva MRI (Philips Healthcare, Netherlands) (UW) using a 
phased -array coil wrapped around the leg at the level of the region of interest.  
9.9.[ADDRESS_926292] likely location of the 
treated segment .  
After the location of the treated segment is identified, a specific se t of MRA s equences will be 
performed. The sequences vary by [CONTACT_15449]. A description of the sequences  and requirements  
is provided in Table 3.  
  
Table 3: Research MRI Sequences  
Sequence  Baseline  
(-30 days)  Within [ADDRESS_926293] -Op 1 Mo  6 Mo  12 Mo  Immediately 
pre re -
intervention  
Pre MERGE  
/DASH  X X X X X X 
2D-T1 X X X X X X 
2D-T2 X X X X X X 
MP RAGE  X X X X X X 
DCE  X  X X  X 
CE-MRA   X   X  
Post  MERGE  
/DASH  X X X X X X 
PC-MRI  X     
 
 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926294] 2019  Page 52 of 72 
 Pre MERGE /DASH (DANTE prepared -FLASH): These sequences are high -resolution, 3D 
black -blood imaging of the vessel wall, which are achieved by [CONTACT_2329] a preparation pulse to null 
the signal from flowing blood. MERGE uses an MSDE ( Motion Sensitive Driving Equilibrium) 
prep-pulse, with a Rapid Gradient Echo acquisition. DASH uses a DANTE prep -pulse ( Delay 
Alternating with Nutation for Tailored Excitation) with a FLASH sequence ( Flash Low Angle 
Shot). These sequences are essentially different implementations to achieve the  same goal of 
vessel wall imaging, and they both contain a motion -sensitive preparation (to null the signal from 
the blood) coupled to a fast gradient echo acquisition.  
 
2D-T1: This is a 2D, high -resolution, T1 weighted sequence. T1 image weighting measure s the 
spin-lattice relaxation time of hydrogen protons in a tissue.  
 
2D-T2: This is a 2D, high -resolution, T2 weighted sequence. T2 image weighting measures the 
spin-spin relaxation time of hydrogen protons in a tissue.  
 
MP RAGE: This is a 3D, T1 -weighted , Magnetization Prepared Rapid Acquisition Gradient Echo 
sequence and provides information about blood degradation products in tissues.  
 
DCE: Dynamic Contrast Enhanced MRI is a T1 -weighted sequence with high temporal 
resolution, acquired after the injection of a gadolinium -based contrast agent  (e.g. Omniscan, 
Gadavist, or ProHance) . This sequence allows for measurement of the passage of contrast 
agent, which gives information about physiological tissue characteristics such as the integrity 
and perfu sion/permeability of the vessel wall. This imaging sequence is used to calculate Ktrans. 
 
The protocol for the Delayed Contrast Enhancement for this study requires an i njection of Gd 
contrast agent:  
A half dose of Gadolinium is injected.  For Magnevist thi s corresponds to (0.1ml of 
Magnevist)/(kg patient weight) and for Gadavist this corresponds to (0.05ml of Gadavist)/(kg 
patient weight of Gadavist).  If Gadavist is used it is diluted 50:[ADDRESS_926295] is used.   
Injection timing:  
The DCE scan is first started.  The contrast should then be injected at the end of the first 
dynamic run, at an injection rate of 1cc/sec, and immediately followed by a saline flush of 15 cc 
saline also at 1cc/sec.  Dynamic scanning should not be not inter rupted during the injection 
delivery.  
 
CE-MRA:  Contrast -Enhanced Magnetic Resonance Angiography is a pulse sequence acquired 
with the simultaneous intravenous injection of a gadolinium -based contrast agent. Gadolinium 
shortens the T1 relaxation time of blo od. This allows for fast image acquisition, with high signal 
intensity in the lumen of vessels (where gadolinium is present), and low signal in extravascular 
territories (where gadolinium is not present). This sequence will give the geometry of the lumen 
used for CFD simulations.  
This sequence is usually acquired after using a timing bolus in order to evaluate the time it takes 
from injection to the arrival of the contrast bolus to the vessel of interest (scan delay). Contrast 
CHR#15 -[ZIP_CODE]    
 
Version #: 1.8 Version Date: [ADDRESS_926296] 2019  Page 53 of 72 
 agent is generally delivered a t 2mL/second.) Typi[INVESTIGATOR_897], the timing bolus is 2mL, 1:1 
gadolinium:saline while the full bolus for CE -MRA is 20mL, also 1:1 gadolinium/saline.  
 
Post  MERGE/DASH:  These 3D black blood sequences are acquired shortly after contrast 
administration to evaluate fo r contrast enhancement (uptake of gadolinium in the vessel wall).  
PC-MRI:  Phase Contrast Magnetic Resonance Imaging is a technique that allows for the 
measurement of blood flow. This is accomplished by [CONTACT_1299] a bipolar gradient along a vessel of 
interest . As hydrogen protons of blood flow along this vessel of interest, they accumulate a 
phase shift that is proportional to their speed. In this way, we are able to non -invasively 
measure the velocity and flow of blood. This sequence will allow description of  the inlet flow 
conditions which will be used to generate CFD models.  
The acquisitions parameters are provided in Appendix [ADDRESS_926297] velocities and B -mode diameter measurements of each segmen t.
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926298] 2019  Page 54 of 72 
 10 SCHEDULE OF  ASSESSMENTS  
Schedule of Assessments continues on the next page    VISIT 1 VISIT 2 VISIT 3 VISIT 4 VISIT 5 VISIT 6 VISIT 7 VISIT 8 UNPLANNED  
VISIT (UV) 
SCREENING  
& BASELINE  
(S & B) PROCEDURE  POST-OP MONTH 1 MONTH 6 MONTH 12 MONTH 24 
(BY [INVESTIGATOR_152979] ) MONTH 36 
(BY [INVESTIGATOR_152979] )  
(-30 days)  (Day 0)  (Day 1 -7) (Day 30¬±7)  (Day 
180¬±14)  (Day 
365¬±30)  (Day 
730¬±30) (Day 
1095¬±30)   
Informed Consent  X          
Inclusion Criteria  X         
Exclusion Criteria  X         
Pregnancy Test  X         
Demographics  X          
Medical History  X          
Concomitant 
medications  X  X X X X X X X 
Vital Signs  X  X X X X   X 
Physical Exam  X  X X X X   X 
Vascular Exam1 X  X X X X   X 
Rutherford Category  X  X X X X   X 
Research Labs2 X  X3 X  X   X 
Clinical Labs  X4  X3 5 X5 X5 X5   X 
Walking Impairment 
Questionnaire  X   X X X    
Research MRI  X  X X X X   X8 
Clinical Ultrasound     X X X   X 
Index Lesion 
Registration   X        
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926299] 2019  Page 55 of 72 
 Schedule of Assessments, continued.  
 
1Vascular exam CRF includes ABI‚Äôs  
2Research labs include CRP, MCP -1, and IL -1Œ≤ 
3For Visit [ADDRESS_926300] -Op, Research & Clinical Labs must be drawn POD #1 -7 
4Clinical labs  for Visit 1  include Serum chemistry, CBC, lipid panel, coagulation studies  
5eGFR only  
6For subjects randomized to DEX  
7For subjects randomized to POBA  (formerly PTX)  
8Perform research MRI, if >[ADDRESS_926301] study MRI  (Continued)  VISIT 1 VISIT 2 VISIT 3 VISIT 4 VISIT 5 VISIT 6 VISIT 7 VISIT 8 UV 
 S & B PROCEDURE  POST-OP MONTH 1 MONTH 6 MONTH 12 MONTH 24 
(BY [INVESTIGATOR_152979] ) MONTH 36 
(BY [INVESTIGATOR_152979] )  
 (-30 days)  (Day 0)  (Day 1 -7) (Day 30¬±7) (Day 180¬±14)  (Day 365¬±30)  (Day 730¬±30)  (Day 1095¬±30)   
Procedural Inclusion & 
Exclusion Criteria   X        
Primary 
Revascularization   X        
Treated Segment 
Registration           
Randomization  
(after successful 
angioplasty)   X        
DEX Infusion6 or  
POBA7  X        
Telephone follow -up       X X  
Adverse Event 
Assessment   X X X X X X X  
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926302] 2019  Page 56 of 72 
  
11 EVALUATIONS BY [CONTACT_16990]   
11.1 Visit 1 : Screening  & Baseline  (Day  -30 to Day -1) 
1. Review the study with the subject and obtain written informed consent and HIPAA 
authoriza tion and assent, if appropriate  
2. Assign the subject a unique study ID  number  
3. Evaluate Inclusion & Exclusion Criteria  
4. Assess childbearing potential of female patients, administer serum Œ≤HCG pregnancy test 
if indicated  
5. Record demographics data  
6. Record  medical history  
7. Record concomitant medications  
8. Perform and record vital signs  
9. Perform a general physical examination  
10. Perform a focused vascular exam  including Ankle -Brachial Index & Rutherford 
Categorization  
11. Collect blood for research  laborat ory tests  (CRP, MCP -1, IL-1Œ≤) 
12. Record results from  standard -of-care clinical laboratory tests (results obtained within 30 
days may be recorded): serum chemistry, C BC, lipid panel, coagulation studies  
13. Administer Walking Impairment Questionnaire (WIQ)  
14. Schedule baseline research  MRI prior to procedure  (up to -30 days allowed)  
11.2 Visit 2: Proce dure (Day 0)  
1. Define index lesion after initial angiogram . Using  Glow ‚ÄòN Tell tape, starting at the medical 
tibial spi[INVESTIGATOR_050] , the index lesion is registered according to its location and length.  
2. If subject is eligible, perform Primary Revascularization (angioplasty of index lesion)  
3. Register the treated segment, location and  length using Glow ‚ÄòN Tell tape.  
4. Assess Procedural Inclusion/Exclusion Criteria  
5. Randomize subject ( see Sec. 9.7‚Äù Randomization ‚Äù & Sec. 16.4 ‚ÄúSample Size and 
Randomization‚Äù ) 
6. For subjects Randomized to DEX, infuse dexamethasone  
7. For subjects Randomized to POBA (formerly PTX), perform  no further treatment  
8. Perform provisional stenting if indicated clinically  
9. Record any procedural Adverse Events  
10. Record any interim Adverse Events  
11.3 Visit 3 : Post -Operative Assessments  (Day 1 -7) 
1. Obtain re search labs (CRP, MCP -1, IL-1Œ≤) on Post -Operative Day  #1 (POD #1 )  
2. Obtain clinical labs (eGFR only)  on Post -Operative Day #1 (POD #1)  
3. Record any changes to medications  
4. Record vital signs  
5. Perform physical exam  
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926303] 2019  Page 57 of 72 
 6. Perform vascular exam  including Ankle -Brachial Index & Rutherford Categorization  
7. Perform research MRI  (up to POD  #7 allowed)   
8. Record any interim Adverse Events  
11.4 Visit 4: 1 Month Follow -up (Day 30 ¬±7) 
1. Record any changes to medications  
2. Record vital signs  
3. Perform physical exam  
4. Perform vascular exam  including Ankle -Brachial Index & Rutherford Categorization  
5. Obtain research labs (CRP, MCP -1, IL-1Œ≤) 
6. Obtain clinical labs (eGFR only)  
7. Administer Walking Impairment Questionnaire  
8. Perform research MRI  
9. Record results of clinical ultrasoun d 
10. Record any interim Adverse Events  
11.5 Visit 5 : 6 Month Follow -up (Day 180 ¬±14) 
1. Record any changes to medications  
2. Record vital signs  
3. Perform physical exam  
4. Perform vascular exam  including Ankle -Brachial Index & Rutherford Categorization  
5. Obtain clinical labs (eG FR only)  
6. Administer Walking Impairment Questionnaire  
7. Perform research MRI  
8. Record results of clinical ultrasound   
9. Record any interim Adverse Events  
11.6 Visit 6 : 12 Month Follow -up (Day 365 ¬±30) 
1. Record any changes to medications  
2. Record vital signs  
3. Perform physical exam  
4. Perform vascular exam  including Ankle -Brachial Index & Rutherford Categorization  
5. Obtain research labs (CRP, MCP -1, IL-1Œ≤) 
6. Administer Walking Impairment Questionnaire  
7. Perform research MRI  
8. Record results of clinical ultrasound   
9. Record any inter im Adverse Events  
11.7 Visit 7: 24 Month Telephone Follow -up (Day 730¬±30) 
10. Record any changes to medications  
11. Record any interim Adverse Events  
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926304] 2019  Page 58 of 72 
 11.8 Visit 8: 36 Month Telephone Follow -up (Day 1095 ¬±30) 
12. Record any changes to medications  
13. Record any interim Adverse Events  
11.[ADDRESS_926305] is unable or unwilling to 
return, the investigator may perform a telephone interview.  
The following information will be recorded at a final clinical appointment:  
1. Record changes to concomitant medications  
2. Perform vascular exam  including Ankle -Brachial Index & Rutherford Categorization  
3. Collect blood for research laboratory tests (CRP, MCP -1, IL-1Œ≤) and safety (eGFR)  
4. Record any interim Adverse Events  
 
The following steps will be performed during a telephone interview:  
1. Record any interim Adverse Events  
2. Arrange for release of records from outside hospi[INVESTIGATOR_600]/providers  
3. Record reason for withdrawal  
11.[ADDRESS_926306] requires reintervention of the index leg, a study visit 
will be performed prior to the reintervention.  
If the need for reintervention is determined within the window of a study visit , all procedures for 
that study visit will be performed.  
If the need for reintervention is determined outside of a study visit window, the following will be 
performed:  
1. Record any changes to medications  
2. Record vital signs  
3. Perform physical exam  
4. Perform vascular exam  including Ankle -Brachial Index & Rutherford Categorization  
5. Obtai n clinical labs (eGFR only)  
6. Administer Walking Impairment Questionnaire  
7. Perform research MRI , if >[ADDRESS_926307] is receiving reintervention on <75% of the treated segment, please continue to follow 
subject  until they have completed the study. For further specifics on study completion, please 
see section 11. 11 Study Completion.    
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926308]:   
1. Undergo follow -up for 36-month period after index procedure, completing all 
assessments in the Schedule of Assessments.  
 
2.  Subject develops restenosis after the 1 -month study follow -up, requiring 
reintervention of ÔÇ≥75% of treated segment.  
If subject does not complete the study following the above indications, please see section 13.1 
for specifics on Early Discontinuation/Withdrawals.  
If subject develops restenosis after the [ADDRESS_926309] udy follow -up, requiring reintervention of 
<75% of the treated segment, please see section 11. 10 for specifics on recording Unplanned 
Visits for Index Leg Reintervention  and continuing follow -up.  
12 ADVERSE EVENT  REPORTING AND DOCUMENTATION  
12.1 Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a clinical investigation of a patient 
administered a pharmaceutical product and that does not necessarily have a causal relationship 
with the treatment.  An AE is therefore any unfavorable and unint ended sign (including an 
abnormal laboratory finding), symptom or disease temporally associated with the administration 
of an investigational product, whether related to that investigational product  or not .  An 
unexpected AE is one of a type not identified in nature, severity, or frequency in the current 
Investigator‚Äôs Brochure or of greater severity or frequency than expected based on the 
information in the Investigator‚Äôs Brochure.  
The Investigator will probe, via discussion with the subject, for  the occurrence of AEs during 
each subject visit and record the information in the site‚Äôs source documents.  Adverse events 
will be recorded in the patient CRF.  Adverse events will be described by [CONTACT_24109] (start and 
stop dates and times), severity, outco me, treatment and relation to the index procedure , or if 
unrelated, the cause.   
AE Severity  
The National Cancer Institute‚Äôs Common Terminology Criteria for Adverse Events (CTCAE) 
Version 3.0 should be used to assess and grade AE severity, including laboratory abnormalities 
judged to be clinically significant. The modified criteria can be found in the study manual.  If the 
experience is not covered in the modified criteria, the guidelines shown  below,  in Table 1, 
should be used to grade severity.  It should be pointed out that the term ‚Äúsevere‚Äù is a measure 
of intensity and that a severe AE is not necessarily serious.  
Table 1.  AE Severity Grading  
Severity (Toxicity Grade)  Description  
Mild (1)  Transient or mild discomfort; no limitation in activity; no medical 
intervention or therapy required. The subject may be aware of 
the sign or symptom but tolerates it reasonably well.  
Moderate (2)  Mild to moderate limitation in activity, no or minimal medical 
intervention/therapy required.  
Severe (3)  Marked limitation in activity, medical intervention/therapy 
required, hospi[INVESTIGATOR_29125].  
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926310] 2019  Page 60 of 72 
  
12.2 Serious Adverse Events  (SAE)  
An SAE is defined as any AE occurring at any dose that results in any of the following 
outcomes:  
‚Ä¢ death  
‚Ä¢ a life -threatening adverse experience  
‚Ä¢ inpatient hospi[INVESTIGATOR_1081]  
‚Ä¢ a persistent or significant disability/incapacity  
‚Ä¢ a congenital anomaly/birth defect  
Other important medical events may also be considered an SAE when, based on appropriate 
medical judgment, they jeopardize the subject or require intervention to prevent one of the 
outcomes listed.  
12.2.1  Serious Adverse Event Reporting  
Study sites will document and report all SAEs that occur (whether or not related to index 
procedure ) within [ADDRESS_926311] (IRB)/Independent Ethics Committee (IEC), the site investigator will report SAEs 
to the IRB/IEC.     
13 DISCONTINUATION AND REPLACEMENT OF SUBJECTS  
13.1 Early  Discontinuation /Withdrawal  
A subject may be discontinued from study treatment at any time if the subject, the investigator, 
or the Sponsor feels that it is not in the subject‚Äôs best interest to continue.  The following is a list 
of possible reasons for st udy treatment discontinuation:  
‚Ä¢ Subject withdrawal of consent (or assent)  
‚Ä¢ Subject is not compliant with study procedures  
‚Ä¢ Adverse event that in the opi[INVESTIGATOR_256029]  (i.e. treated  segment restenosis /occlusion 
occurring between index procedure date and the 1 -month study follow -up date ) 
‚Ä¢ Protocol violation requiring discontinuation of study treatment  
‚Ä¢ Positive pregnancy test (females)  
‚Ä¢ Lost to follow -up 
‚Ä¢ Death  
If a subject is withdrawn from treatment due to an adverse event, the subject will be followed 
and treated by [CONTACT_256058].   Life-threatening (4)  The subject is at risk of death due to the adverse experience as 
it occurred. This does not refer to an experience that 
hypothetically might have caused death if it were more severe.  
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926312]‚Äôs withdrawal from the study will be specified in the 
subject‚Äôs source documents.  
  
13.[ADDRESS_926313] safety and primary endpoint criteria.  
Protocol violations for this study include, but are not limited to, the following:  
‚Ä¢ Failure to meet inclusi on/exclusion criteria  
‚Ä¢ Use of a prohibited concomitant medication  
‚Ä¢ Failure to comply with Good Clinical Practice (GCP) guidelines will also result in a 
protocol violation. The Investigator  will determine if a protocol violation will result in 
withdrawal of a  subject.  
When a protocol violation occurs, it will be discussed with the investigator and a Protocol 
Violation Form detailing the violation will be generated. This form will be signed by [CONTACT_3786]. A copy of the form will be filed in the site‚Äôs reg ulatory binder and in the Sponsor‚Äôs 
files. 
 
15 DATA SAFETY MONITORING  
Since this is a multi -institution al study, a Data Monitoring C ommittee  (DMC)  comprised of the 
principal investigator, two co -investigato rs (Drs. Hatsukami and Gasper ) will meet on a regular  
semi -annual basis to review the progress of the trial and address all safety issues. The minutes 
of the meetings will be submitted to the UCSF institutional review board.  
All Serious Adverse Events (SAEs) will be reported  to the IRB within 5 business days  of 
investigator awareness  (or as per local IRB policy), followed to resolution and adjudicated. 
Adverse Events will also be grouped and analyzed in the following three distinct periods:  
1. From intervention through discharge from hospi[INVESTIGATOR_307];  
2. From hospi[INVESTIGATOR_683903] 1 -month evaluation; and  
3. Beyond the 1 -month evaluation and through 36 months and completion of study 
participation.  
Adverse events will be documented on the AE Case Report Form. Those SA Es that are 
possibly related to the treatm ent (angioplasty, infusion  or drug), the procedure  (angiogram, 
access vessel, etc.), or the disease state being treated (PAD) may be reviewed and  adjudicated 
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926314] 2019  Page 62 of 72 
 by [CONTACT_683942]. All Serious Adverse Events and/or Unanticipated Adverse Device  
Effects  will be reported to the IRB per the IRB‚Äôs specific policies and guidelines.  
[ADDRESS_926315]-
operative  (1-7 days after intervention)  MRI scan to 12 months between DEX  treated and non-
DEX (PTX or POBA)  treated patients.  
Statistical hypothesis  1a: Adventitial DEX infusion will result in reduced change in percent wall 
volume (PWV) within the treated segment . 
Statistical Methods:  The p rimary analysis  will be an intention -to-treat (ITT) comparison of 
observed change in mean ŒîPWV between treatment group s at [ADDRESS_926316]. 
Because ŒîPWV may be nonlinear in time, linear splines with knots at 24 hours, 1 month, 6 
months, and 12 months will be used to fit the model. Multivariable regression models will be 
constructed to determine independent variab les associated with ŒîPWV controlling  for 
demographic and anatomical variables, statin use, inflammatory markers, and smoking. We will 
also investigate effects by [CONTACT_683943], clin ical, and anatomic variables. Predictors of PWV will be 
evaluated via univariate and multivariate regression analysis.  
16.3 Analysis of Secondary Endpoints  
Statistical hypothesis  1b: Adventitial DEX infusion will result in improved vascular remodeling 
of the treated segment.  
Statistical Methods: ITT comparison of observed change in remodeling between treatment 
groups at [ADDRESS_926317] 
both been hypothesized to influence vessel remodeling.  
 
Statistical hypothesis  2a: Adventitial DEX infusion will result in reduced peri -operative 
inflammatory profile . 
Statistical Methods: Each biomarker will be tested for normality and log -transformed as 
necessary. Descriptive statistics will record the mean and standard deviation (or median and 
inter-quartile range) of each biomarker at each time po int. Then, the area under the curve (AUC) 
will be calculated for each biomarker from baseline, [ADDRESS_926318]. 
 
  
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926319] 2019  Page 63 of 72 
 Statistical hypothesis  2b: Adventitial DEX infusion will result in less adventitial perfusion (a 
surrogate of  inflammation) as measured by [CONTACT_683939] -enhanced MRI . 
Statistical Methods:  ITT Comparisons will be made between average Ktrans values of the two 
treatment groups using the Wilcoxon signed rank test. Spearman rank correlation coefficient will 
be determined between VP and Ktrans values, and other variables such as smoking status, statin 
use, plaque component, and biomarker levels. Ktrans will also be assessed at baseline  MRI visit  
as a parameter of plaque inflammation for descriptive purposes. Ktrans will likely be difficult to 
assess in the freshly injured artery at the 24 hour MR I. 
 
Statistical hypothesis  2c: Peri-operative inflammatory profile will be associated with ŒîPWV . 
Statistical Methods:  Pearson correlation coefficients will be calculated between CRP, MCP -1, 
and IL -1Œ≤ and confounding factors such as diabetes, foot ulcer, and treated segment length, 
etc. Multivariable linear regression models will be created with each inflammatory marker A UC 
as the dependent variable in order to determine the independent effect of inflammation on 
ŒîPWV.  
 
Statistical hypothesis  3a:  Treat ed segment remodeling will be associated with the fibrous 
volume in the plaque.  
Statistical Methods:    Multi -contrast MRI will be used to determine the relative volumes of 
fibrous, calcification, and LRNC expressed as a percent of TVV for each treated segment in this 
study. Pearson‚Äôs correlation coefficient will be used to determine if patient -related factors or 
markers of in flammation are associated with plaque composition. Then multivariable regression 
equations will be generated to determine if fibrous tissue content is associated with remodeling. 
Models will be constructed with and without DEX to determine if DEX will chan ge the Œ≤ -
coefficient of the association between fibrous tissue content and remodeling.  
 
Statistical hypothesis  3b: Treat ed segment remodeling/ŒîPWV will be associated with wall 
shear stress provided by [CONTACT_9268] -determined, patient -specific, geometry and computat ional fluid 
dynamics  
Statistical Methods: Hemodynamic parameters WSS, WSSG, and OSI, derived from CFD will 
be calculated at each MRI time point. Multivariable regression models will be constructed to 
determine the independent contribution of these paramete rs on treat ed segment remodeling 
and ŒîPWV.  
Interim analyses will be made prior to DMC meetings and in preparation of publications.  
16.4 Sample Size and Randomization  
The sample size for this study is based on Statistical Hypothesis 1a. While there are no 
predicate serial studies of PWV changes in femoral artery restenosis following PTA to estimate 
the sample size, previous work on the progression of de novo atherosclerosis in similar sized 
peripheral arteries (carotids) forms the basis of this estimation  (please refer to Section 1.2  
reference numbers 70 and 71) . Power calculations were performed based on an expected 
reproducibility variance of 8% (determined from evaluations performed on measurements 
performed on the untreated leg for studies at multiple ti me points).  An effect size of 6.3% or 7% 
was assumed based on data from pi[INVESTIGATOR_7602]. Based on power calculations, we estimate the 
need for 22 subjects/treatment assignment to detect a 7% difference in PWV at a power level of 
80%. Assigning a 20% attriti on rate due to loss to follow up or index lesion revascularization, 27 
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926320] at a 5% significance 
level.  
 
Overall sample size providing 80% power in 2 -sided 5% tests  
Between -group 
difference  Measurement error  
7% 8% 9% 
6.3%  42 54 68 
7% 34 44 54 
 
The Principal Investigator‚Äôs staff will develop and maintain a block randomizations scheme for 
each site. The scheme will be developed using Stata 12.1 (StataCorp, College Station, TX, 
[LOCATION_003]) with a 1: 2 allocation  of DEX:POBA because the [ADDRESS_926321] once the Procedural Inclusion/Exclusion Criteria 
are assessed.  Figure  6 illustrates the Study Enrollment and Randomization process.  
 
Figure 6 : Enrollment and Randomization process  
 

CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926322]‚Äôs 
visit into the protocol -specific electronic Case Report Form (eCRF) when the information 
corresponding to that visit is available.  Subjects will not be identified by [CONTACT_2300] i n the study 
database  but will be identified by a subject number.  
If a correction is required for an eCRF, the  time and date stamps track the person entering or 
updating eCRF data and creates an electronic audit trail. If a correction  is made on a paper 
source form , the study staff member will line through the incorrect data, write in the correct data 
and initial and date the change.  
The Investigator is responsible for all information collected on subjects enrolled in this study.  All 
data collected during the course of this study must be reviewed and verified for completeness 
and accuracy by [CONTACT_737].  A copy of the CRF will remain at the Investigator‚Äôs site at the 
completion of the study  pursuant to institutional record retent ion guidelines . 
17.[ADDRESS_926323] laboratories as appropriate for 
analyses. Data will be coded or deidentified , according to the matrix in Appendix III ‚Äì Data 
Management. The code will be maintained and kept secure by [CONTACT_87137].  
17.[ADDRESS_926324] unauthorized access by [CONTACT_683944]; 
appropriate backup copi[INVESTIGATOR_92287].   Databases  are backed up by [CONTACT_256059].    
At critical junctures of  the protocol (e.g., production of interim reports and final reports), data for 
analysis is locked and cleaned per established procedures.  
17.[ADDRESS_926325] make study data accessible to the monitor , other authorized 
representatives of the Sponsor (or designee), IRB/IEC, and Regulatory Agency (e.g., FDA) 
inspectors upon request.  A file for each subject must be maintained that includes the signed 
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926326] ensure the reliability and 
availability of source documents from which the information on the CRF was derived.  
All study documents (patient files, signed informed consen t forms, copi[INVESTIGATOR_3110], Study File 
Notebook, etc.) mu st be kept secured and retained according VA  & UW IRB  policies.  
17.[ADDRESS_926327] organizations .  
18 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS  
The study will be conducted according to the Declaration of Helsinki, Protection of Human 
Volunteers ( 21 CFR 50), Institutional Review Boards (21 CFR 56), and Obligations of Clinical 
Investigators (21 CFR 312).  
To maintain confidentiality, all laboratory specimens, evaluation forms, reports and other 
records will be identified by a coded number and initial s only.  All study records will be kept in a 
locked file cabinet and code sheets linking a patient‚Äôs name [CONTACT_1639] a patient identification number 
will be stored separately in another locked file cabinet.  Clinical information will not be released 
without writte n permission of the subject, except as necessary for monitoring by [CONTACT_1622].  The 
Investigator must also comply with all applicable privacy regulations (e.g., Health Insurance 
Portability and Accountability Act of 1996, EU Data Protection Directive 95/46/EC ). 
18.1 Protocol Amendments  
Any amendment to the protocol will be written by [CONTACT_737] .  Protocol amendments cannot  
be implemented without prior written IRB/IEC approval except as necessary to eliminate 
immediate safety hazards to patients.  A protocol a mendment intended to eliminate an apparent 
immediate hazard to patients may be implemented immediately, provided the IRBs are notified 
within five working days.  
18.2 Institutional Review Boards and Independent Ethics Committees  
The protocol and consent form wil l be reviewed and approved by [CONTACT_1201]/IEC of each 
participating center prior to study initiation.  Serious adverse experiences regardless of causality 
will be reported to the IRB/IEC in accordance with the standard operating procedures and 
policies of the IRB/IEC, and the Investigator will keep the IRB/IEC informed as to the progress 
of the study.  The Investigator will obtain assurance of IRB/IEC compliance with regulations.  
Any documents that the IRB/IEC may need to fulfill its responsibilities (such as p rotocol, 
protocol amendments, Investigator‚Äôs Brochure, consent forms, information concerning patient 
recruitment, payment or compensation procedures, or other pertinent information) will be 
submitted to the IRB/IEC.  The IRB/IECs written unconditional appr oval of the study protocol 
and the informed consent form will be in the possession of the Investigator before the study is 
initiated.  The IRB/IECs unconditional approval statement will be transmitted by [CONTACT_683945] o f study supplies to the site.  This approval must refer to the 
study by [CONTACT_256061].  
Protocol and/or informed consent modifications or changes may not be initiated withou t prior 
written IRB/IEC approval except when necessary to eliminate immediate hazards to the patients 
or when the change(s) involves only logistical or administrative aspects of the study.  Such 
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926328] 2019  Page 67 of 72 
 modifications will be submitted to the IRB/IEC and written ve rification that the modification was 
submitted and subsequently approved should be obtained.   
The IRB/IEC must be informed of revisions to other documents originally submitted for review; 
serious and/or unexpected adverse experiences occurring during the study in accordance with 
the standard operating procedures and policies of the IRB; new information that may affect 
adversely the safety of the patients of the conduct of the study; an annual update and/or request 
for re -approval; and when the study has be en completed.  
18.3 Informed Consent Form  
Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH GCP, US 
Code of Federal Regulations for Protection of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, 
and CFR Part 56, Subpart A), the Health Insurance Portability and Accountability Act (HIPAA, if 
applicable), and local regulations.  
The Investigator will prepare the informed consent form, assent and HIPAA authorization and 
provide the documents to the Sponsor or designee for approval pri or to submission to the 
IRB/IEC.  The consent form generated by [CONTACT_683946]/IEC.  The written consent document will embody the elements of 
informed consent as described in the International Conference on Harmonisation and will also 
comply with local regulations. The Investigator will send an IRB/IEC -approved copy of the 
Informed Consent Form to the Sponsor (or designee) for the study file.  
A properly executed, written, informed consent will b e obtained from each subject prior to 
entering the subject into the trial.  Information should be given in both oral and written form and 
subjects must be given ample opportunity to inquire about details of the study.  If appropriate 
and required by [CONTACT_683947]/IEC, assent from the subject will also be obtained.  If a subject is 
unable to sign the informed consent form (ICF) and the HIPAA authorization, a legal 
representative may sign for the subject.   A copy of the signed consent form (and assent) will be 
given to the subject and the original will be maintained with the subject‚Äôs records.  
18.[ADDRESS_926329]  of 1996.  
18.5 Investigator Responsibilities  
By [CONTACT_29184], the Investigator agrees to:  
1. Conduct the study in accordance with the protocol and only make changes after notifying 
the Sponsor (or designee), except when to protect the safety, rights or welfare of subjects.  
2. Personally conduct or supervise the study (or investigation).  
3. Ensure that t he requirements relating to obtaining informed consent and IRB review and 
approval meet federal guidelines, as stated in ¬ß 21 CFR, parts 50 and 56.  
4. Report to the Sponsor or designee any AEs that occur in the course of the study, in 
accordance with ¬ß[ADDRESS_926330] of the study 
are informed about their obligations in meeting the above commitments.  
CHR#15 -[ZIP_CODE]   Confidential  
 
Version #: 1.8 Version Date: [ADDRESS_926331] 2019  Page 68 of 72 
 6. Maintain adequate and accurate records in accordance with ¬ß21 CFR 312.62 and to make 
those records available for inspection with the Sponsor (or designee).  
7. Ensure that an IRB that complies with the requirements of ¬ß21 CFR part 56 will be 
responsible for initial and continuing review and approval of the clinical study.  
8. Promptly report to the  IRB and the Sponsor (or designee) all changes in the research 
activity and all unanticipated problems involving risks to subjects or others (to include 
amendments and IND safety reports).  
9. Seek IRB approval before any changes are made in the research study , except when 
necessary to eliminate hazards to the patients/subjects.  
10. Comply with all other requirements regarding the obligations of clinical investigators and all 
other pertinent requirements listed in ¬ß 21 CFR part 312.  
 
CHR# 15-[ZIP_CODE]  Confidential  
Version #: 1.8 Version Date: [ADDRESS_926332] 2019  Page 69 of 72 
Protocol Template ¬© CFFT TDN   Effective: 12 SEP  2007  APPENDIX 1 .  SAMPLE COLLECTION & PROCESSING GUIDELINES  
 
Tube Matrix  
Tube  Volume 
(ml) Processing  Centrifuge  Aliquot to  Storage  
Tiger Top SST  10 Allow to clot 30-
60 min  4¬∞C, 2800 RPM, 
10 min  Serum, 4x2ml 
cryovials  -80¬∞C  
Lavender EDTA  10 Process 
immediately  4¬∞C, 2800 RPM, 
10 min  Plasma, 4x2ml 
cryovials  -80¬∞C  
 
Assay Matrix  
Assay  Obtained from  
CRP  [ADDRESS_926333]  
IL-1Œ≤ 10 ml Lavender 
EDTA  
 
  
CHR# 15-[ZIP_CODE]  Confidential  
Version #: 1.8 Version Date: [ADDRESS_926334] 2019  Page 70 of 72 
Protocol Template ¬© CFFT TDN   Effective: 12 SEP  2007  APPENDIX 2 .  DATA MANAGEMENT  
 
Individual/Institution  Role  Role  Dataset  Coded  Deidentified  
David Saloner, PhD  Principal -
investigator  Analysis, manuscript 
preparation  Full dataset  As 
appropriate  No 
Chun Yua n, PhD  Co-investigator  Analysis, manuscript 
preparation  Full dataset  As 
appropriate  No 
Warren Gasper, MD  Co-investigator  Analysis, manuscript 
preparation  Full dataset  As 
appropriate  No 
Thomas Hatsukami, MD  Co-investigator  Analysis, manuscript 
preparation  Full dataset  As 
appropriate  No 
Michael Hope, MD  Co-investigator  Analysis, manuscript 
preparation  Full dataset  As 
appropriate  No 
Balu Niranjan, PhD  Co-investigator  Analysis, manuscript 
preparation  Full dataset  As 
appropriate  No 
Niten Singh, MD  Co-investigator  Analysis, manuscript 
preparation  Full dataset  As 
appropriate  No 
DMC  Safety monitoring  Interim safety analyses   descriptive 
statistics, adverse 
event descriptions, 
prepared by [CONTACT_683948] ‚Äôs Hospi[INVESTIGATOR_398313]: Dept. of 
Laboratory Medicine, 
CERLab  Contract lab  Inflammatory Marker 
analysis  Manifests 
containing subject 
IDs Yes No 
CHR# 15-[ZIP_CODE]  Confidential  
Version #: 1.8 Version Date: [ADDRESS_926335] 
3D-
MERGE  
(3D Dash)  MP-RAGE  2D T1w  2D T2w  DCE  CE-MRA  PC-MRI 
Mode  3D 3D 2D 2D 2D 3D 2D 
Acquisition  plane  Coronal  Coronal  Axial  Axial  Axial  Coronal  Axial  
Black -blood prep  MSDE 
(DANTE)   MSDE  MSDE     
Resolution, mm2 1.0 (0.8) 1.0 0.7 0.7 0.7 0.7 0.5 
FOV, mm2 300√ó360 
(324x370)  300x360  120x300 
(160x300)  120x300 
(160x300)  120x300  300x360  160x300  
Slice thickness , mm  0.7 (0.8)  0.7 3 3 4 0.7 5 
# of slices  150 (104)  150 16 16 8 150 2 
TR/TE, ms  8/4 (7/3.4)  8/5 800/10  4500/40  8/4 8/4 5/3 
Flip angle, ¬∞  6 (8) 11   15  20 
Turbo factor  25 (100)  100 14 10    
NSA 1 1 2 1 1 1 1 
No of stations  1 1 1 1 1 1 2 
Scan time (min)  3.5  (4.5)  4.5 12 6 5 2 2 
CHR# 15-[ZIP_CODE]  Confidential  
Version #: 1.8 Version Date: [ADDRESS_926336] ADMIRAL DCB CATHETER IFU  
APPENDIX 8. STELLAREX DCB CATHETER IFU  
APPENDIX 9 . WALKING IMPAIRMENT QUESTIONNAIRE (WIQ)  
 
 